Clinical trial results:
Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes

Summary

EudraCT number	2015-003997-33
Trial protocol	BE DE GB ES AT NL BG SE PL CZ HU PT GR DK IT RO
Global end of trial date	31 December 2023

Results information

Result version number	v1 (current)
This version publication date	28 April 2024
First version publication date	28 April 2024
Summary attachment (see zip file)	Clinical Study Report NOAH - AFNET 6 (NOAH_CSR_231221.pdf)

Trial information

Trial identification

Sponsor protocol code	NOAH-AFNET6

Additional study identifiers

ISRCTN number	ISRCTN17309850
ClinicalTrials.gov id (NCT number)	NCT02618577
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]
Sponsor organisation address	Mendelstraße 11, Münster, Germany, 48149
Public contact	Clinical Trials Information AFNET, Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork], +49 2519801340, info@kompetenznetz-vorhofflimmern.de
Scientific contact	Clinical Trials Information AFNET, Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork], +49 2519801340, info@kompetenznetz-vorhofflimmern.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 December 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	25 August 2023
Global end of trial reached?	Yes
Global end of trial date	31 December 2023
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To demonstrate that oral anticoagulation with the NOAC edoxaban is superior to current therapy (antiplatelet therapy or no therapy depending on cardio-vascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE but without overt AF and at least two stroke risk factors leading to a modified CHA2DS2VASc score of 2 or more.

Protection of trial subjects:

A Data and Safety Monitoring Board (DSMB) was established to ensure independent monitoring of patient safety.
All data obtained in the context of the clinical trial are subject to data protection.
The patients will be advised in the informed consent forms that they have the right to withdraw from study participation at any time without statement of reasons.

Background therapy: -

Evidence for comparator:

ASA has been used for decades as standard therapeutic agent for antithrombotic therapy according to corresponding medical guidelines. Within NOAH - AFNET 6 either tablets of 100 mg ASA will be applied or matching placebo tablets.

Actual start date of recruitment	15 March 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Ukraine: 354
Country: Number of subjects enrolled	Poland: 277
Country: Number of subjects enrolled	Netherlands: 49
Country: Number of subjects enrolled	Portugal: 25
Country: Number of subjects enrolled	Romania: 14
Country: Number of subjects enrolled	Spain: 370
Country: Number of subjects enrolled	Sweden: 16
Country: Number of subjects enrolled	United Kingdom: 167
Country: Number of subjects enrolled	Austria: 238
Country: Number of subjects enrolled	Belgium: 28
Country: Number of subjects enrolled	Bulgaria: 22
Country: Number of subjects enrolled	Czechia: 12
Country: Number of subjects enrolled	Denmark: 18
Country: Number of subjects enrolled	France: 97
Country: Number of subjects enrolled	Germany: 727

Country: Number of subjects enrolled	Greece: 8
Country: Number of subjects enrolled	Hungary: 70
Country: Number of subjects enrolled	Italy: 169
Worldwide total number of subjects	2661
EEA total number of subjects	2140

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1
From 65 to 84 years	2243
85 years and over	417

Subject disposition

Recruitment

Recruitment details:

Patients were recruited by contracted study sites only with adequate experience in follow-up of implanted pacemakers, defibrillators or insertable cardiac monitors in clinical routine and in treatment of patients with AF.

Pre-assignment

Screening details:

Adult patients aged ≥65 with atrial high rate episodes (duration at least 6 min and frequency at least 170 bpm), detected by implantable devices and a CHA2DS2VASc score of 2 or more.

Pre-assignment period milestones

Number of subjects started	2661
Number of subjects completed	

Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Subject, Data analyst

Arms

Are arms mutually exclusive?	Yes
Arm title	"NOAC" group

Arm description:

In the "NOAC" group one edoxaban tablet plus one placebo tablet matching in colour, weight, form and size to ASA 100 mg will be administered per day irrespective of stratum according to indication for use of antiplatelet therapy. The use of edoxaban eliminates the necessity of parallel intake of ASA 100 mg in case of an indication for use of antiplatelet therapy.

Arm type	Experimental
Investigational medicinal product name	edoxaban
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the "NOAC" group one edoxaban tablet plus one placebo tablet matching in colour, weight, form and size to ASA 100 mg will be administered per day irrespective of stratum according to indication for use of antiplatelet therapy. The use of edoxaban eliminates the necessity of parallel intake of ASA 100 mg in case of an indication for use of antiplatelet therapy.
Edoxaban will be used in NOAH - AFNET 6 at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:
- Impaired renal function (CrCl 15-50 ml/min), or
- low body weight (≤60 kg), or
- patients receiving the p-glycoprotein inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.

Arm title	"Usual Care" group

Arm description:

In the "Usual Care" group either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be

adminis-tered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator.

Arm type	Active comparator or placebo
Investigational medicinal product name	ASA
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

In the “Usual Care” group either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator.

Number of subjects in period 1[1]	"NOAC” group	“Usual Care” group
Started	1306	1302
Completed	1270	1264
Not completed	36	38
Consent withdrawn by subject	24	32
other reasons	4	1
No adequate AHRE	5	3
Documented atrial fibrillation after randomization	3	2

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: The modified intention to treat population (mITT) consists of all randomised patients with a qualifying AHRE and intake of at least one dose of study drug. The mITT doesn't include patients that were randomized but a) have AF onset before 1st dose of Investigational medicinal product (IMP), or b) die before 1st dose of IMP, c) withdrew their consent before 1st dose of IMP or d) are lost to follow-up before 1st dose of the IMP.

Baseline characteristics

Reporting groups	
Reporting group title	"NOAC" group

Reporting group description:

In the "NOAC" group one edoxaban tablet plus one placebo tablet matching in colour, weight, form and size to ASA 100 mg will be administered per day irrespective of stratum according to indication for use of antiplatelet therapy. The use of edoxaban eliminates the necessity of parallel intake of ASA 100 mg in case of an indication for use of antiplatelet therapy.

Reporting group title	"Usual Care" group

Reporting group description:

In the "Usual Care" group either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator.

Reporting group values	"NOAC" group	"Usual Care" group	Total
Number of subjects	1306	1302	2608
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
arithmetic mean	77.47	77.59	
standard deviation	± 6.57	± 6.79	-
Gender categorical Units: Subjects			
Female	483	495	978
Male	823	807	1630

Subject analysis sets	
Subject analysis set title	mITT
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

The primary analysis is in the modified intention-to-treat population, consisting of all randomised patients with a qualifying AHRE and intake of at least one dose of study drug.

Reporting group values	mITT		
Number of subjects	2534		
Age categorical Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous Units: years			
arithmetic mean	77.46		
standard deviation	± 6.65		
Gender categorical Units: Subjects			
Female	947		
Male	1587		

End points

End points reporting groups

Reporting group title	"NOAC" group

Reporting group description:

In the "NOAC" group one edoxaban tablet plus one placebo tablet matching in colour, weight, form and size to ASA 100 mg will be administered per day irrespective of stratum according to indication for use of antiplatelet therapy. The use of edoxaban eliminates the necessity of parallel intake of ASA 100 mg in case of an indication for use of antiplatelet therapy.

Reporting group title	"Usual Care" group

Reporting group description:

In the "Usual Care" group either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator.

Subject analysis set title	mITT
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

The primary analysis is in the modified intention-to-treat population, consisting of all randomised patients with a qualifying AHRE and intake of at least one dose of study drug.

Primary: First Primary Outcome

End point title	First Primary Outcome

End point description:

The primary endpoint is the time from randomisation to the first occurrence of stroke, systemic embolism or cardiovascular death.

End point type	Primary

End point timeframe:

Overall trial

End point values	"NOAC" group	"Usual Care" group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1270	1264		
Units: Events				
first occurrence of stroke	22	27		
systemic embolism	14	28		
cardiovascular death	52	57		
Composite	83	101		

Statistical analyses

Statistical analysis title	Time-to-event analysis

Statistical analysis description:

A cause-specific Cox proportional hazards model is used, along with the Breslow method to handle tied time points for events, with a frailty term for the trial site, the trial-group assignment as a predictor variable, and the randomization strata indication for acetylsalicylic acid as a covariate.

Comparison groups	"NOAC" group v "Usual Care" group

Number of subjects included in analysis	2534
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1476
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	1.08

Secondary: Composite safety endpoint

End point title	Composite safety endpoint

End point description:

The safety endpoint is the time from randomisation to the first occurrence of major bleeding or all-cause death.

End point type	Secondary

End point timeframe:

Overall trial

End point values	"NOAC" group	"Usual Care" group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1270	1264		
Units: Events				
major bleeding	53	25		
all-cause death	111	94		
Composite	149	114		

Statistical analyses

Statistical analysis title	Time-to-event analysis

Statistical analysis description:

A cause-specific Cox proportional hazards model is used, along with the Breslow method to handle tied time points for events, with a frailty term for the trial site, the trial-group assignment as a predictor variable, and the randomization strata indication for acetylsalicylic acid as a covariate.

Comparison groups	"NOAC" group v "Usual Care" group

Number of subjects included in analysis	2534
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0325
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.02
upper limit	1.67

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.1

Reporting groups

Reporting group title	Edoxaban

Reporting group description: -

Reporting group title	Placebo

Reporting group description: -

Serious adverse events	Edoxaban	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	498 / 1306 (38.13%)	467 / 1302 (35.87%)	
number of deaths (all causes)	142	125	
number of deaths resulting from adverse events	142	125	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Abdominal neoplasm	Additional description: Abdominal neoplasm		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myeloid leukaemia	Additional description: Acute myeloid leukaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon	Additional description: Adenocarcinoma of colon		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma gastric	Additional description: Adenocarcinoma gastric		

subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Basal cell carcinoma	Additional description: Basal cell carcinoma		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of bladder	Additional description: Benign neoplasm of bladder		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer	Additional description: Bladder cancer		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Bladder transitional cell carcinoma recurrent	Additional description: Bladder transitional cell carcinoma recurrent		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowen's disease	Additional description: Bowen's disease		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone cancer metastatic	Additional description: Bone cancer metastatic		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer	Additional description: Breast cancer		
subjects affected / exposed	1 / 1306 (0.08%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial carcinoma	Additional description: Bronchial carcinoma		

subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Carcinoma in situ of skin	Additional description: Carcinoma in situ of skin		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma	Additional description: Cholangiocarcinoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Chronic lymphocytic leukaemia	Additional description: Chronic lymphocytic leukaemia		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Colorectal adenoma	Additional description: Colorectal adenoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon neoplasm	Additional description: Colon neoplasm		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer	Additional description: Colon cancer		
subjects affected / exposed	10 / 1306 (0.77%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 14	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 1	
Endometrial cancer	Additional description: Endometrial cancer		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gammopathy	Additional description: Gammopathy		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer	Additional description: Gastric cancer		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 6	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastric neoplasm	Additional description: Gastric neoplasm		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastrointestinal carcinoma	Additional description: Gastrointestinal carcinoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypergammaglobulinaemia benign monoclonal	Additional description: Hypergammaglobulinaemia benign monoclonal		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer	Additional description: Laryngeal cancer		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lipoma	Additional description: Lipoma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung cancer metastatic	Additional description: Lung cancer metastatic		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Lung neoplasm malignant	Additional description: Lung neoplasm malignant		

subjects affected / exposed	8 / 1306 (0.61%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	1 / 11	0 / 9	
deaths causally related to treatment / all	1 / 5	0 / 3	
Lymphoma	Additional description: Lymphoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma	Additional description: Meningioma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone	Additional description: Metastases to bone		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesothelioma malignant	Additional description: Mesothelioma malignant		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system	Additional description: Metastases to central nervous system		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to liver	Additional description: Metastases to liver		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Metastases to lung	Additional description: Metastases to lung		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lymph nodes	Additional description: Metastases to lymph nodes		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to pleura	Additional description: Metastases to pleura		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to the mediastinum	Additional description: Metastases to the mediastinum		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastasis	Additional description: Metastasis		
subjects affected / exposed	7 / 1306 (0.54%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 5	0 / 2	
Metastases to pancreas	Additional description: Metastases to pancreas		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelodysplastic syndrome	Additional description: Myelodysplastic syndrome		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Myelofibrosis	Additional description: Myelofibrosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Neoplasm malignant	Additional description: Neoplasm malignant		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 3	
Nasal sinus cancer	Additional description: Nasal sinus cancer		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm	Additional description: Neoplasm		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Non-Hodgkin's lymphoma	Additional description: Non-Hodgkin's lymphoma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma	Additional description: Oesophageal adenocarcinoma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oesophageal carcinoma	Additional description: Oesophageal carcinoma		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian adenoma	Additional description: Ovarian adenoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer	Additional description: Ovarian cancer		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic neoplasm	Additional description: Pancreatic neoplasm		
subjects affected / exposed	4 / 1306 (0.31%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma	Additional description: Pancreatic carcinoma		

subjects affected / exposed	5 / 1306 (0.38%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 3	0 / 1	
Pancreatic carcinoma metastatic	Additional description: Pancreatic carcinoma metastatic		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma	Additional description: Plasma cell myeloma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal cancer	Additional description: Pharyngeal cancer		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural mesothelioma	Additional description: Pleural mesothelioma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural mesothelioma malignant	Additional description: Pleural mesothelioma malignant		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Prostate cancer	Additional description: Prostate cancer		
subjects affected / exposed	9 / 1306 (0.69%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	1 / 9	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer metastatic	Additional description: Prostate cancer metastatic		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Rectal adenocarcinoma	Additional description: Rectal adenocarcinoma		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer	Additional description: Rectal cancer		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal neoplasm	Additional description: Rectal neoplasm		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectosigmoid cancer	Additional description: Rectosigmoid cancer		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal cancer	Additional description: Renal cancer		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer stage IV	Additional description: Renal cancer stage IV		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal neoplasm	Additional description: Renal neoplasm		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland cancer	Additional description: Salivary gland cancer		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland neoplasm	Additional description: Salivary gland neoplasm		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma	Additional description: Squamous cell carcinoma		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma of head and neck	Additional description: Squamous cell carcinoma of head and neck		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung	Additional description: Squamous cell carcinoma of lung		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin	Additional description: Squamous cell carcinoma of skin		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity	Additional description: Squamous cell carcinoma of the oral cavity		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer	Additional description: Tonsil cancer		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm malignant stage unspecified	Additional description: Tongue neoplasm malignant stage unspecified		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma	Additional description: Transitional cell carcinoma		

subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tumour haemorrhage	Additional description: Tumour haemorrhage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal cancer	Additional description: Vaginal cancer		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Angiodysplasia	Additional description: Angiodysplasia		
subjects affected / exposed	5 / 1306 (0.38%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	4 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm	Additional description: Aortic aneurysm		
subjects affected / exposed	4 / 1306 (0.31%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic stenosis	Additional description: Aortic stenosis		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial haemorrhage	Additional description: Arterial haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bleeding varicose vein	Additional description: Bleeding varicose vein		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse	Additional description: Circulatory collapse		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis	Additional description: Deep vein thrombosis		
subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism arterial	Additional description: Embolism arterial		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Giant cell arteritis	Additional description: Giant cell arteritis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma	Additional description: Haematoma		
subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	2 / 4	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage	Additional description: Haemorrhage		
subjects affected / exposed	18 / 1306 (1.38%)	10 / 1302 (0.77%)	
occurrences causally related to treatment / all	6 / 20	3 / 10	
deaths causally related to treatment / all	1 / 4	0 / 2	
Hypertension	Additional description: Hypertension		
subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis	Additional description: Hypertensive crisis		
subjects affected / exposed	3 / 1306 (0.23%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 4	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency	Additional description: Hypertensive emergency		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension	Additional description: Hypotension		
subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoedema	Additional description: Lymphoedema		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension	Additional description: Orthostatic hypotension		
subjects affected / exposed	4 / 1306 (0.31%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis	Additional description: Peripheral artery stenosis		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery occlusion	Additional description: Peripheral artery occlusion		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease	Additional description: Peripheral arterial occlusive disease		
subjects affected / exposed	7 / 1306 (0.54%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 1	
Peripheral embolism	Additional description: Peripheral embolism		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia	Additional description: Peripheral ischaemia		

subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Superficial vein thrombosis	Additional description: Superficial vein thrombosis		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis	Additional description: Thrombosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis	Additional description: Thrombophlebitis		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis	Additional description: Venous thrombosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous stenosis	Additional description: Venous stenosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis	Additional description: Vasculitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Abdominal cavity drainage	Additional description: Abdominal cavity drainage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess drainage	Additional description: Abscess drainage		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Abdominal wall operation	Additional description: Abdominal wall operation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amputation	Additional description: Amputation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aneurysm repair	Additional description: Aneurysm repair		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal lesion excision	Additional description: Anal lesion excision		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm repair	Additional description: Aortic aneurysm repair		
subjects affected / exposed	4 / 1306 (0.31%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angioplasty	Additional description: Angioplasty		
subjects affected / exposed	5 / 1306 (0.38%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve replacement	Additional description: Aortic valve replacement		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Aortic stent insertion	Additional description: Aortic stent insertion		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic bypass	Additional description: Aortic bypass		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial aneurysm repair	Additional description: Arterial aneurysm repair		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicectomy	Additional description: Appendicectomy		
subjects affected / exposed	2 / 1306 (0.15%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial stent insertion	Additional description: Arterial stent insertion		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula operation	Additional description: Arteriovenous fistula operation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthrodesis	Additional description: Arthrodesis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial appendage closure	Additional description: Atrial appendage closure		
subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stent insertion	Additional description: Bile duct stent insertion		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stent removal	Additional description: Bile duct stent removal		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary catheter insertion	Additional description: Biliary catheter insertion		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder catheter removal	Additional description: Bladder catheter removal		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder catheter temporary	Additional description: Bladder catheter temporary		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder catheterisation	Additional description: Bladder catheterisation		
subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm surgery	Additional description: Bladder neoplasm surgery		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder polypectomy	Additional description: Bladder polypectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brachytherapy	Additional description: Brachytherapy		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast conserving surgery	Additional description: Breast conserving surgery		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast prosthesis removal	Additional description: Breast prosthesis removal		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bunion operation	Additional description: Bunion operation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursa removal	Additional description: Bursa removal		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cancer surgery	Additional description: Cancer surgery		
subjects affected / exposed	3 / 1306 (0.23%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac ablation	Additional description: Cardiac ablation		
subjects affected / exposed	15 / 1306 (1.15%)	15 / 1302 (1.15%)	
occurrences causally related to treatment / all	0 / 16	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker adjustment	Additional description: Cardiac pacemaker adjustment		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker insertion	Additional description: Cardiac pacemaker insertion		

subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker removal	Additional description: Cardiac pacemaker removal		
subjects affected / exposed	2 / 1306 (0.15%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker replacement	Additional description: Cardiac pacemaker replacement		
subjects affected / exposed	38 / 1306 (2.91%)	57 / 1302 (4.38%)	
occurrences causally related to treatment / all	0 / 39	0 / 58	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac resynchronisation therapy	Additional description: Cardiac resynchronisation therapy		
subjects affected / exposed	19 / 1306 (1.45%)	13 / 1302 (1.00%)	
occurrences causally related to treatment / all	0 / 20	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardioversion	Additional description: Cardioversion		
subjects affected / exposed	21 / 1306 (1.61%)	21 / 1302 (1.61%)	
occurrences causally related to treatment / all	0 / 29	0 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract operation	Additional description: Cataract operation		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid endarterectomy	Additional description: Carotid endarterectomy		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central venous catheterisation	Additional description: Central venous catheterisation		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central venous catheter removal	Additional description: Central venous catheter removal		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chemotherapy	Additional description: Chemotherapy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystectomy	Additional description: Cholecystectomy		
subjects affected / exposed	11 / 1306 (0.84%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	1 / 11	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithotomy	Additional description: Cholelithotomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circumcision	Additional description: Circumcision		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colectomy	Additional description: Colectomy		
subjects affected / exposed	8 / 1306 (0.61%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 9	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Colostomy	Additional description: Colostomy		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Coronary artery bypass	Additional description: Coronary artery bypass		
subjects affected / exposed	5 / 1306 (0.38%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
Coronary arterial stent insertion	Additional description: Coronary arterial stent insertion		

subjects affected / exposed	29 / 1306 (2.22%)	27 / 1302 (2.07%)	
occurrences causally related to treatment / all	0 / 32	0 / 30	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary angioplasty	Additional description: Coronary angioplasty		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cyst drainage	Additional description: Cyst drainage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corpora cavernosa surgery	Additional description: Corpora cavernosa surgery		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniectomy	Additional description: Craniectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Debridement	Additional description: Debridement		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytoreductive surgery	Additional description: Cytoreductive surgery		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal sphincterotomy	Additional description: Duodenal sphincterotomy		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenectomy	Additional description: Duodenectomy		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear tube insertion	Additional description: Ear tube insertion		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocoagulation	Additional description: Electrocoagulation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endarterectomy	Additional description: Endarterectomy		
subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eventration repair	Additional description: Eventration repair		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid operation	Additional description: Eyelid operation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot amputation	Additional description: Foot amputation		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrectomy	Additional description: Gastrectomy		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal endoscopic therapy	Additional description: Gastrointestinal endoscopic therapy		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glossectomy	Additional description: Glossectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrostomy	Additional description: Gastrostomy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma evacuation	Additional description: Haematoma evacuation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemodialysis	Additional description: Haemodialysis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoid operation	Additional description: Haemorrhoid operation		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia repair	Additional description: Hernia repair		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	1 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip arthroplasty	Additional description: Hip arthroplasty		
subjects affected / exposed	16 / 1306 (1.23%)	11 / 1302 (0.84%)	
occurrences causally related to treatment / all	0 / 17	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip surgery	Additional description: Hip surgery		

subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hospitalisation	Additional description: Hospitalisation		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
High frequency ablation	Additional description: High frequency ablation		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileostomy	Additional description: Ileostomy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Immunochemotherapy	Additional description: Immunochemotherapy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia repair	Additional description: Inguinal hernia repair		
subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infiltration anaesthesia	Additional description: Infiltration anaesthesia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Internal fixation of fracture	Additional description: Internal fixation of fracture		
subjects affected / exposed	9 / 1306 (0.69%)	9 / 1302 (0.69%)	
occurrences causally related to treatment / all	0 / 10	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal operation	Additional description: Intestinal operation		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraocular lens implant	Additional description: Intraocular lens implant		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-aortic balloon placement	Additional description: Intra-aortic balloon placement		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Knee arthroplasty	Additional description: Knee arthroplasty		
subjects affected / exposed	6 / 1306 (0.46%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint fluid drainage	Additional description: Joint fluid drainage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jejunectomy	Additional description: Jejunectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laparotomy	Additional description: Laparotomy		
subjects affected / exposed	5 / 1306 (0.38%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	1 / 5	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Laparoscopic surgery	Additional description: Laparoscopic surgery		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee operation	Additional description: Knee operation		

subjects affected / exposed	1 / 1306 (0.08%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal polypectomy	Additional description: Large intestinal polypectomy		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	2 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal prosthesis placement	Additional description: Laryngeal prosthesis placement		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal operation	Additional description: Laryngeal operation		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngectomy	Additional description: Laryngectomy		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lesion excision	Additional description: Lesion excision		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lithotripsy	Additional description: Lithotripsy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver ablation	Additional description: Liver ablation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb amputation	Additional description: Limb amputation		

subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Liver operation	Additional description: Liver operation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung lobectomy	Additional description: Lung lobectomy		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mammoplasty	Additional description: Mammoplasty		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device implantation	Additional description: Medical device implantation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenectomy	Additional description: Lymphadenectomy		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma surgery	Additional description: Meningioma surgery		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve repair	Additional description: Mitral valve repair		
subjects affected / exposed	3 / 1306 (0.23%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck dissection	Additional description: Neck dissection		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrectomy	Additional description: Nephrectomy		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrostomy	Additional description: Nephrostomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal prosthesis insertion	Additional description: Oesophageal prosthesis insertion		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal dilation procedure	Additional description: Oesophageal dilation procedure		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthopaedic procedure	Additional description: Orthopaedic procedure		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreaticoduodenectomy	Additional description: Pancreaticoduodenectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroidectomy	Additional description: Parathyroidectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paracentesis	Additional description: Paracentesis		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parotidectomy	Additional description: Parotidectomy		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial drainage	Additional description: Pericardial drainage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic operation	Additional description: Pelvic operation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Percutaneous coronary intervention	Additional description: Percutaneous coronary intervention		
subjects affected / exposed	28 / 1306 (2.14%)	36 / 1302 (2.76%)	
occurrences causally related to treatment / all	1 / 33	0 / 39	
deaths causally related to treatment / all	0 / 0	0 / 1	
Peripheral artery angioplasty	Additional description: Peripheral artery angioplasty		
subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery bypass	Additional description: Peripheral artery bypass		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stent insertion	Additional description: Peripheral artery stent insertion		
subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral nerve destruction	Additional description: Peripheral nerve destruction		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal fistula repair	Additional description: Pharyngeal fistula repair		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal operation	Additional description: Pharyngeal operation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurectomy	Additional description: Pleurectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polypectomy	Additional description: Polypectomy		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Positive airway pressure therapy	Additional description: Positive airway pressure therapy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctectomy	Additional description: Proctectomy		
subjects affected / exposed	5 / 1306 (0.38%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatectomy	Additional description: Prostatectomy		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ptosis repair	Additional description: Ptosis repair		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiotherapy	Additional description: Radiotherapy		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiotherapy to lung	Additional description: Radiotherapy to lung		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiotherapy to rectum	Additional description: Radiotherapy to rectum		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal prolapse repair	Additional description: Rectal prolapse repair		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Removal of internal fixation	Additional description: Removal of internal fixation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal stone removal	Additional description: Renal stone removal		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Resuscitation	Additional description: Resuscitation		
subjects affected / exposed	1 / 1306 (0.08%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 4	
Shoulder operation	Additional description: Shoulder operation		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin neoplasm excision	Additional description: Skin neoplasm excision		
subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal resection	Additional description: Small intestinal resection		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal laminectomy	Additional description: Spinal laminectomy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal operation	Additional description: Spinal operation		
subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal decompression	Additional description: Spinal decompression		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgery	Additional description: Surgery		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Therapeutic procedure	Additional description: Therapeutic procedure		
subjects affected / exposed	16 / 1306 (1.23%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	10 / 22	1 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Thoracic cavity drainage	Additional description: Thoracic cavity drainage		

subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombectomy	Additional description: Thrombectomy		
subjects affected / exposed	2 / 1306 (0.15%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Thrombolysis	Additional description: Thrombolysis		
subjects affected / exposed	0 / 1306 (0.00%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Thyroidectomy	Additional description: Thyroidectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toe amputation	Additional description: Toe amputation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transcatheter aortic valve implantation	Additional description: Transcatheter aortic valve implantation		
subjects affected / exposed	6 / 1306 (0.46%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheostomy	Additional description: Tracheostomy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transfusion	Additional description: Transfusion		
subjects affected / exposed	58 / 1306 (4.44%)	28 / 1302 (2.15%)	
occurrences causally related to treatment / all	23 / 78	3 / 37	
deaths causally related to treatment / all	1 / 8	0 / 4	
Transurethral prostatectomy	Additional description: Transurethral prostatectomy		

subjects affected / exposed	5 / 1306 (0.38%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour excision	Additional description: Tumour excision		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transurethral bladder resection	Additional description: Transurethral bladder resection		
subjects affected / exposed	9 / 1306 (0.69%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	1 / 11	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia repair	Additional description: Umbilical hernia repair		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteral stent insertion	Additional description: Ureteral stent insertion		
subjects affected / exposed	4 / 1306 (0.31%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteral stent removal	Additional description: Ureteral stent removal		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethrotomy	Additional description: Urethrotomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary cystectomy	Additional description: Urinary cystectomy		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence surgery	Additional description: Urinary incontinence surgery		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse repair	Additional description: Uterine prolapse repair		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular operation	Additional description: Vascular operation		
subjects affected / exposed	2 / 1306 (0.15%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vaginal prolapse repair	Additional description: Vaginal prolapse repair		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein operation	Additional description: Varicose vein operation		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitrectomy	Additional description: Vitrectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord operation	Additional description: Vocal cord operation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Adverse drug reaction	Additional description: Adverse drug reaction		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia	Additional description: Asthenia		

subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 3	0 / 2	
Cardiac death	Additional description: Cardiac death		
subjects affected / exposed	21 / 1306 (1.61%)	22 / 1302 (1.69%)	
occurrences causally related to treatment / all	0 / 21	0 / 22	
deaths causally related to treatment / all	0 / 21	0 / 21	
Chest pain	Additional description: Chest pain		
subjects affected / exposed	5 / 1306 (0.38%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death	Additional description: Death		
subjects affected / exposed	103 / 1306 (7.89%)	87 / 1302 (6.68%)	
occurrences causally related to treatment / all	4 / 103	0 / 88	
deaths causally related to treatment / all	4 / 102	0 / 87	
Gait disturbance	Additional description: Gait disturbance		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration	Additional description: General physical health deterioration		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing	Additional description: Impaired healing		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multimorbidity	Additional description: Multimorbidity		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Multiple organ dysfunction syndrome	Additional description: Multiple organ dysfunction syndrome		

subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	1 / 2	0 / 1	
Non-cardiac chest pain	Additional description: Non-cardiac chest pain		
subjects affected / exposed	6 / 1306 (0.46%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema	Additional description: Oedema		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral	Additional description: Oedema peripheral		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pacemaker generated arrhythmia	Additional description: Pacemaker generated arrhythmia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain	Additional description: Pain		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral swelling	Additional description: Peripheral swelling		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Puncture site haemorrhage	Additional description: Puncture site haemorrhage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pyrexia	Additional description: Pyrexia		

subjects affected / exposed	5 / 1306 (0.38%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death	Additional description: Sudden cardiac death		
subjects affected / exposed	18 / 1306 (1.38%)	15 / 1302 (1.15%)	
occurrences causally related to treatment / all	0 / 18	0 / 15	
deaths causally related to treatment / all	0 / 18	0 / 15	
Systemic inflammatory response syndrome	Additional description: Systemic inflammatory response syndrome		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Ulcer	Additional description: Ulcer		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Hypersensitivity	Additional description: Hypersensitivity		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Genital lesion	Additional description: Genital lesion		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis	Additional description: Prostatitis		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Vaginal haemorrhage	Additional description: Vaginal haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse	Additional description: Uterine prolapse		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal prolapse	Additional description: Vaginal prolapse		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome	Additional description: Acute respiratory distress syndrome		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspiration	Additional description: Aspiration		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Asthma	Additional description: Asthma		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease	Additional description: Chronic obstructive pulmonary disease		
subjects affected / exposed	8 / 1306 (0.61%)	8 / 1302 (0.61%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cystic lung disease	Additional description: Cystic lung disease		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cough	Additional description: Cough		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Dyspnoea	Additional description: Dyspnoea		
subjects affected / exposed	8 / 1306 (0.61%)	8 / 1302 (0.61%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	

Emphysema	Additional description: Emphysema		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	

Epistaxis	Additional description: Epistaxis		
subjects affected / exposed	5 / 1306 (0.38%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	1 / 5	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Haemoptysis	Additional description: Haemoptysis		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Haemothorax	Additional description: Haemothorax		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Interstitial lung disease	Additional description: Interstitial lung disease		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Nasal septum deviation	Additional description: Nasal septum deviation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Obstructive sleep apnoea syndrome	Additional description: Obstructive sleep apnoea syndrome

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion	Additional description: Pleural effusion		
subjects affected / exposed	8 / 1306 (0.61%)	8 / 1302 (0.61%)	
occurrences causally related to treatment / all	0 / 8	0 / 10	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pneumonitis	Additional description: Pneumonitis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax	Additional description: Pneumothorax		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism	Additional description: Pulmonary embolism		
subjects affected / exposed	3 / 1306 (0.23%)	10 / 1302 (0.77%)	
occurrences causally related to treatment / all	0 / 3	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary fibrosis	Additional description: Pulmonary fibrosis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary hypertension	Additional description: Pulmonary hypertension		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema	Additional description: Pulmonary oedema		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mass	Additional description: Pulmonary mass		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory acidosis	Additional description: Respiratory acidosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure	Additional description: Respiratory failure		
subjects affected / exposed	11 / 1306 (0.84%)	7 / 1302 (0.54%)	
occurrences causally related to treatment / all	1 / 11	0 / 7	
deaths causally related to treatment / all	1 / 6	0 / 2	
Restrictive pulmonary disease	Additional description: Restrictive pulmonary disease		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep apnoea syndrome	Additional description: Sleep apnoea syndrome		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic haemorrhage	Additional description: Thoracic haemorrhage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Aggression	Additional description: Aggression		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Agitation	Additional description: Agitation		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic idiopathic pain syndrome	Additional description: Chronic idiopathic pain syndrome		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Completed suicide	Additional description: Completed suicide		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Confusional state	Additional description: Confusional state		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression	Additional description: Depression		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium	Additional description: Delirium		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disturbance in social behaviour	Additional description: Disturbance in social behaviour		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disorientation	Additional description: Disorientation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug abuse	Additional description: Drug abuse		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Drug dependence	Additional description: Drug dependence		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Insomnia	Additional description: Insomnia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental disorder	Additional description: Mental disorder		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt	Additional description: Suicide attempt		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device lead issue	Additional description: Device lead issue		
subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device inappropriate shock delivery	Additional description: Device inappropriate shock delivery		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device dislocation	Additional description: Device dislocation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction	Additional description: Device malfunction		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device occlusion	Additional description: Device occlusion		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lead dislodgement	Additional description: Lead dislodgement		
subjects affected / exposed	1 / 1306 (0.08%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Undersensing	Additional description: Undersensing		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone	Additional description: Bile duct stone		
subjects affected / exposed	6 / 1306 (0.46%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic	Additional description: Biliary colic		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary tract disorder	Additional description: Biliary tract disorder		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cholangitis	Additional description: Cholangitis		
subjects affected / exposed	3 / 1306 (0.23%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cholelithiasis	Additional description: Cholelithiasis		
subjects affected / exposed	5 / 1306 (0.38%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute	Additional description: Cholecystitis acute		

subjects affected / exposed	8 / 1306 (0.61%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cholestasis	Additional description: Cholestasis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic lesion	Additional description: Hepatic lesion		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cyst	Additional description: Hepatic cyst		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice cholestatic	Additional description: Jaundice cholestatic		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice	Additional description: Jaundice		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Liver disorder	Additional description: Liver disorder		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post cholecystectomy syndrome	Additional description: Post cholecystectomy syndrome		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Angiocardiogram	Additional description: Angiocardiogram		

subjects affected / exposed	20 / 1306 (1.53%)	26 / 1302 (2.00%)	
occurrences causally related to treatment / all	1 / 22	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiogram	Additional description: Angiogram		
subjects affected / exposed	1 / 1306 (0.08%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriogram carotid	Additional description: Arteriogram carotid		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspiration joint	Additional description: Aspiration joint		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspiration pleural cavity	Additional description: Aspiration pleural cavity		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy	Additional description: Biopsy		
subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy adrenal gland	Additional description: Biopsy adrenal gland		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy bladder	Additional description: Biopsy bladder		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy heart	Additional description: Biopsy heart		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy lymph gland	Additional description: Biopsy lymph gland		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy lung	Additional description: Biopsy lung		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy kidney	Additional description: Biopsy kidney		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy pericardium	Additional description: Biopsy pericardium		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy skin	Additional description: Biopsy skin		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biopsy prostate	Additional description: Biopsy prostate		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Capsule endoscopy	Additional description: Capsule endoscopy		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac electrophysiologic study	Additional description: Cardiac electrophysiologic study		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker evaluation	Additional description: Cardiac pacemaker evaluation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheterisation cardiac	Additional description: Catheterisation cardiac		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonoscopy	Additional description: Colonoscopy		
subjects affected / exposed	37 / 1306 (2.83%)	20 / 1302 (1.54%)	
occurrences causally related to treatment / all	19 / 45	6 / 21	
deaths causally related to treatment / all	1 / 1	0 / 1	
Coronavirus test positive	Additional description: Coronavirus test positive		
subjects affected / exposed	34 / 1306 (2.60%)	36 / 1302 (2.76%)	
occurrences causally related to treatment / all	1 / 41	0 / 37	
deaths causally related to treatment / all	1 / 16	0 / 17	
Cystoscopy	Additional description: Cystoscopy		
subjects affected / exposed	4 / 1306 (0.31%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diagnostic procedure	Additional description: Diagnostic procedure		
subjects affected / exposed	40 / 1306 (3.06%)	16 / 1302 (1.23%)	
occurrences causally related to treatment / all	16 / 48	4 / 18	
deaths causally related to treatment / all	0 / 1	0 / 1	
Electrocardiogram ambulatory	Additional description: Electrocardiogram ambulatory		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endoscopic retrograde cholangiopancreatography	Additional description: Endoscopic retrograde cholangiopancreatography		

subjects affected / exposed	14 / 1306 (1.07%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	0 / 17	0 / 6	
deaths causally related to treatment / all	0 / 2	0 / 1	
Endoscopy small intestine	Additional description: Endoscopy small intestine		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endoscopy upper gastrointestinal tract	Additional description: Endoscopy upper gastrointestinal tract		
subjects affected / exposed	54 / 1306 (4.13%)	23 / 1302 (1.77%)	
occurrences causally related to treatment / all	24 / 64	4 / 27	
deaths causally related to treatment / all	1 / 3	0 / 1	
Human rhinovirus test positive	Additional description: Human rhinovirus test positive		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinoscopy	Additional description: Mediastinoscopy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal manometry	Additional description: Oesophageal manometry		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagogastroduodenoscopy	Additional description: Oesophagogastroduodenoscopy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranasal biopsy	Additional description: Paranasal biopsy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumovirus test positive	Additional description: Pneumovirus test positive		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep study	Additional description: Sleep study		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteroscopy abnormal	Additional description: Ureteroscopy abnormal		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venogram	Additional description: Venogram		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral test negative	Additional description: Viral test negative		
subjects affected / exposed	95 / 1306 (7.27%)	93 / 1302 (7.14%)	
occurrences causally related to treatment / all	7 / 130	2 / 122	
deaths causally related to treatment / all	0 / 3	0 / 8	
Weight decreased	Additional description: Weight decreased		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accident at home	Additional description: Accident at home		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acetabulum fracture	Additional description: Acetabulum fracture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula aneurysm	Additional description: Arteriovenous fistula aneurysm		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial injury	Additional description: Arterial injury		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac procedure complication	Additional description: Cardiac procedure complication		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cervical vertebral fracture	Additional description: Cervical vertebral fracture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion	Additional description: Concussion		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Compression fracture	Additional description: Compression fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complications of transplanted kidney	Additional description: Complications of transplanted kidney		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion	Additional description: Contusion		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniofacial fracture	Additional description: Craniofacial fracture		

subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury	Additional description: Craniocerebral injury		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Fall	Additional description: Fall		
subjects affected / exposed	16 / 1306 (1.23%)	20 / 1302 (1.54%)	
occurrences causally related to treatment / all	2 / 17	2 / 23	
deaths causally related to treatment / all	1 / 2	0 / 1	
Femoral neck fracture	Additional description: Femoral neck fracture		
subjects affected / exposed	3 / 1306 (0.23%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture	Additional description: Femur fracture		
subjects affected / exposed	9 / 1306 (0.69%)	10 / 1302 (0.77%)	
occurrences causally related to treatment / all	0 / 9	0 / 10	
deaths causally related to treatment / all	0 / 1	0 / 1	
Fibula fracture	Additional description: Fibula fracture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture	Additional description: Forearm fracture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fractured sacrum	Additional description: Fractured sacrum		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury	Additional description: Head injury		

subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	1 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture	Additional description: Hip fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture	Additional description: Humerus fracture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immunisation reaction	Additional description: Immunisation reaction		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury	Additional description: Injury		
subjects affected / exposed	3 / 1306 (0.23%)	7 / 1302 (0.54%)	
occurrences causally related to treatment / all	0 / 4	1 / 7	
deaths causally related to treatment / all	0 / 1	0 / 1	
Intentional overdose	Additional description: Intentional overdose		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaw fracture	Additional description: Jaw fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation	Additional description: Joint dislocation		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury	Additional description: Joint injury		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip injury	Additional description: Lip injury		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury	Additional description: Limb injury		
subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture	Additional description: Lumbar vertebral fracture		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures	Additional description: Multiple fractures		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Multiple injuries	Additional description: Multiple injuries		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Nasal injury	Additional description: Nasal injury		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoradionecrosis	Additional description: Osteoradionecrosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture	Additional description: Pelvic fracture		

subjects affected / exposed	3 / 1306 (0.23%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Patella fracture	Additional description: Patella fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital haematoma	Additional description: Periorbital haematoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage	Additional description: Post procedural haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	1 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma	Additional description: Post procedural haematoma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural haemorrhage	Additional description: Procedural haemorrhage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture	Additional description: Radius fracture		
subjects affected / exposed	3 / 1306 (0.23%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reactive gastropathy	Additional description: Reactive gastropathy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture	Additional description: Rib fracture		

subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident	Additional description: Road traffic accident		
subjects affected / exposed	5 / 1306 (0.38%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Scrotal haematoma	Additional description: Scrotal haematoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration	Additional description: Skin laceration		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture	Additional description: Skull fracture		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 1	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column injury	Additional description: Spinal column injury		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Spinal fracture	Additional description: Spinal fracture		
subjects affected / exposed	4 / 1306 (0.31%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Subdural haematoma	Additional description: Subdural haematoma		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	1 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Stoma complication	Additional description: Stoma complication		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sternal fracture	Additional description: Sternal fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage	Additional description: Subdural haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Tibia fracture	Additional description: Tibia fracture		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents	Additional description: Toxicity to various agents		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haematoma	Additional description: Traumatic haematoma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm	Additional description: Vascular pseudoaneurysm		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Haemophilia	Additional description: Haemophilia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phimosis	Additional description: Phimosis		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome	Additional description: Acute coronary syndrome		
subjects affected / exposed	3 / 1306 (0.23%)	9 / 1302 (0.69%)	
occurrences causally related to treatment / all	0 / 3	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute myocardial infarction	Additional description: Acute myocardial infarction		
subjects affected / exposed	14 / 1306 (1.07%)	19 / 1302 (1.46%)	
occurrences causally related to treatment / all	0 / 20	0 / 21	
deaths causally related to treatment / all	0 / 2	0 / 4	
Angina pectoris	Additional description: Angina pectoris		
subjects affected / exposed	14 / 1306 (1.07%)	11 / 1302 (0.84%)	
occurrences causally related to treatment / all	0 / 17	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable	Additional description: Angina unstable		
subjects affected / exposed	2 / 1306 (0.15%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis	Additional description: Aortic valve stenosis		
subjects affected / exposed	4 / 1306 (0.31%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation	Additional description: Atrial fibrillation		
subjects affected / exposed	38 / 1306 (2.91%)	39 / 1302 (3.00%)	
occurrences causally related to treatment / all	0 / 50	0 / 51	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter	Additional description: Atrial flutter		
subjects affected / exposed	6 / 1306 (0.46%)	11 / 1302 (0.84%)	
occurrences causally related to treatment / all	0 / 7	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial thrombosis	Additional description: Atrial thrombosis		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left	Additional description: Bundle branch block left		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure	Additional description: Cardiac failure		
subjects affected / exposed	93 / 1306 (7.12%)	90 / 1302 (6.91%)	
occurrences causally related to treatment / all	1 / 145	0 / 131	
deaths causally related to treatment / all	0 / 22	0 / 19	
Cardiac failure acute	Additional description: Cardiac failure acute		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac amyloidosis	Additional description: Cardiac amyloidosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest	Additional description: Cardiac arrest		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Cardiac failure congestive	Additional description: Cardiac failure congestive		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock	Additional description: Cardiogenic shock		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiomyopathy	Additional description: Cardiomyopathy		

subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular disorder	Additional description: Cardiovascular disorder		
subjects affected / exposed	6 / 1306 (0.46%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 6	0 / 6	
Coronary artery disease	Additional description: Coronary artery disease		
subjects affected / exposed	7 / 1306 (0.54%)	8 / 1302 (0.61%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dilated cardiomyopathy	Additional description: Dilated cardiomyopathy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extrasystoles	Additional description: Extrasystoles		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cardiomyopathy	Additional description: Ischaemic cardiomyopathy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracardiac thrombus	Additional description: Intracardiac thrombus		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence	Additional description: Mitral valve incompetence		
subjects affected / exposed	3 / 1306 (0.23%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve stenosis	Additional description: Mitral valve stenosis		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction	Additional description: Myocardial infarction		
subjects affected / exposed	5 / 1306 (0.38%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	1 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia	Additional description: Myocardial ischaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Palpitations	Additional description: Palpitations		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion	Additional description: Pericardial effusion		
subjects affected / exposed	4 / 1306 (0.31%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis	Additional description: Pericarditis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia	Additional description: Sinus tachycardia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia	Additional description: Tachyarrhythmia		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia	Additional description: Tachycardia		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tricuspid valve incompetence	Additional description: Tricuspid valve incompetence		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia	Additional description: Ventricular arrhythmia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia	Additional description: Ventricular tachycardia		
subjects affected / exposed	5 / 1306 (0.38%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation	Additional description: Ventricular fibrillation		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ventricular extrasystoles	Additional description: Ventricular extrasystoles		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Amnesia	Additional description: Amnesia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery aneurysm	Additional description: Carotid artery aneurysm		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis	Additional description: Carotid artery stenosis		

subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cauda equina syndrome	Additional description: Cauda equina syndrome		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome	Additional description: Carpal tunnel syndrome		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar haemorrhage	Additional description: Cerebellar haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haematoma	Additional description: Cerebral haematoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Cerebral small vessel ischaemic disease	Additional description: Cerebral small vessel ischaemic disease		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage	Additional description: Cerebral haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	2 / 2	1 / 3	
deaths causally related to treatment / all	1 / 1	0 / 0	
Cerebrovascular accident	Additional description: Cerebrovascular accident		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cervicobrachial syndrome	Additional description: Cervicobrachial syndrome		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder	Additional description: Cognitive disorder		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia Alzheimer's type	Additional description: Dementia Alzheimer's type		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Dementia	Additional description: Dementia		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy	Additional description: Diabetic neuropathy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disturbance in attention	Additional description: Disturbance in attention		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness	Additional description: Dizziness		
subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic stroke	Additional description: Embolic stroke		
subjects affected / exposed	7 / 1306 (0.54%)	9 / 1302 (0.69%)	
occurrences causally related to treatment / all	0 / 7	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 4	
Epilepsy	Additional description: Epilepsy		

subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-Barre syndrome	Additional description: Guillain-Barre syndrome		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial	Additional description: Haemorrhage intracranial		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic stroke	Additional description: Haemorrhagic stroke		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic transformation stroke	Additional description: Haemorrhagic transformation stroke		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache	Additional description: Headache		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke	Additional description: Ischaemic stroke		
subjects affected / exposed	25 / 1306 (1.91%)	29 / 1302 (2.23%)	
occurrences causally related to treatment / all	0 / 25	0 / 30	
deaths causally related to treatment / all	0 / 2	0 / 5	
Lacunar stroke	Additional description: Lacunar stroke		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness	Additional description: Loss of consciousness		

subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Memory impairment	Additional description: Memory impairment		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy	Additional description: Metabolic encephalopathy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nystagmus	Additional description: Nystagmus		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorder	Additional description: Nervous system disorder		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraplegia	Additional description: Paraplegia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinson's disease	Additional description: Parkinson's disease		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Parkinsonism	Additional description: Parkinsonism		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy	Additional description: Polyneuropathy		

subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Presyncope	Additional description: Presyncope	
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)
occurrences causally related to treatment / all	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Restless legs syndrome	Additional description: Restless legs syndrome	
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Sciatica	Additional description: Sciatica	
subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)
occurrences causally related to treatment / all	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Seizure	Additional description: Seizure	
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Speech disorder	Additional description: Speech disorder	
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Subarachnoid haemorrhage	Additional description: Subarachnoid haemorrhage	
subjects affected / exposed	2 / 1306 (0.15%)	4 / 1302 (0.31%)
occurrences causally related to treatment / all	0 / 2	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Syncope	Additional description: Syncope	
subjects affected / exposed	9 / 1306 (0.69%)	9 / 1302 (0.69%)
occurrences causally related to treatment / all	1 / 11	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0
Transient global amnesia	Additional description: Transient global amnesia	

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack	Additional description: Transient ischaemic attack		
subjects affected / exposed	6 / 1306 (0.46%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia	Additional description: Anaemia		
subjects affected / exposed	44 / 1306 (3.37%)	16 / 1302 (1.23%)	
occurrences causally related to treatment / all	20 / 55	3 / 26	
deaths causally related to treatment / all	1 / 2	0 / 2	
Anaemia vitamin B12 deficiency	Additional description: Anaemia vitamin B12 deficiency		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy	Additional description: Lymphadenopathy		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy mediastinal	Additional description: Lymphadenopathy mediastinal		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paratracheal lymphadenopathy	Additional description: Paratracheal lymphadenopathy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			

Ear haemorrhage	Additional description: Ear haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear pain	Additional description: Ear pain		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden hearing loss	Additional description: Sudden hearing loss		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tinnitus	Additional description: Tinnitus		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo	Additional description: Vertigo		
subjects affected / exposed	4 / 1306 (0.31%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Amaurosis fugax	Additional description: Amaurosis fugax		
subjects affected / exposed	4 / 1306 (0.31%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye haemorrhage	Additional description: Eye haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion	Additional description: Retinal artery occlusion		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage	Additional description: Retinal haemorrhage		

subjects affected / exposed	0 / 1306 (0.00%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein occlusion	Additional description: Retinal vein occlusion		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein thrombosis	Additional description: Retinal vein thrombosis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vision blurred	Additional description: Vision blurred		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual field defect	Additional description: Visual field defect		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreoretinal traction syndrome	Additional description: Vitreoretinal traction syndrome		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal distension	Additional description: Abdominal distension		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain	Additional description: Abdominal pain		
subjects affected / exposed	5 / 1306 (0.38%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal incarcerated hernia	Additional description: Abdominal incarcerated hernia		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Abdominal pain upper	Additional description: Abdominal pain upper		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Barrett's oesophagus	Additional description: Barrett's oesophagus		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis	Additional description: Colitis		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic	Additional description: Colitis ischaemic		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Constipation	Additional description: Constipation		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea	Additional description: Diarrhoea		
subjects affected / exposed	9 / 1306 (0.69%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 9	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum	Additional description: Diverticulum		
subjects affected / exposed	4 / 1306 (0.31%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	3 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis	Additional description: Duodenitis		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage	Additional description: Duodenal ulcer haemorrhage		
subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	1 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis	Additional description: Enteritis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecaloma	Additional description: Faecaloma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic	Additional description: Gastritis haemorrhagic		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis	Additional description: Gastritis		
subjects affected / exposed	5 / 1306 (0.38%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	1 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive	Additional description: Gastritis erosive		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastric ulcer	Additional description: Gastric ulcer		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal perforation	Additional description: Gastrointestinal perforation		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastrointestinal necrosis	Additional description: Gastrointestinal necrosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastrointestinal obstruction	Additional description: Gastrointestinal obstruction		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage	Additional description: Gastrointestinal haemorrhage		
subjects affected / exposed	50 / 1306 (3.83%)	19 / 1302 (1.46%)	
occurrences causally related to treatment / all	34 / 66	3 / 23	
deaths causally related to treatment / all	0 / 4	0 / 3	
Gastrointestinal ulcer haemorrhage	Additional description: Gastrointestinal ulcer haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal vascular malformation haemorrhagic	Additional description: Gastrointestinal vascular malformation haemorrhagic		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease	Additional description: Gastrooesophageal reflux disease		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis	Additional description: Haematemesis		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia	Additional description: Haematochezia		

subjects affected / exposed	6 / 1306 (0.46%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	4 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage	Additional description: Haemorrhoidal haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids	Additional description: Haemorrhoids		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids thrombosed	Additional description: Haemorrhoids thrombosed		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia	Additional description: Hiatus hernia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus	Additional description: Ileus		
subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia	Additional description: Inguinal hernia		
subjects affected / exposed	0 / 1306 (0.00%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage	Additional description: Intestinal haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Intestinal perforation	Additional description: Intestinal perforation		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intestinal polyp	Additional description: Intestinal polyp		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haemorrhage	Additional description: Intra-abdominal haemorrhage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp	Additional description: Large intestine polyp		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation	Additional description: Large intestine perforation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Melaena	Additional description: Melaena		
subjects affected / exposed	4 / 1306 (0.31%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	2 / 4	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric artery embolism	Additional description: Mesenteric artery embolism		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Oesophageal haemorrhage	Additional description: Oesophageal haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal mucosa erythema	Additional description: Oesophageal mucosa erythema		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal stenosis	Additional description: Oesophageal stenosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer	Additional description: Oesophageal ulcer		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis	Additional description: Pancreatitis		
subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatitis acute	Additional description: Pancreatitis acute		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis	Additional description: Proctitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis haemorrhagic	Additional description: Proctitis haemorrhagic		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal prolapse	Additional description: Rectal prolapse		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage	Additional description: Rectal haemorrhage		

subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	3 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haematoma	Additional description: Retroperitoneal haematoma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia	Additional description: Umbilical hernia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage	Additional description: Upper gastrointestinal haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varices oesophageal	Additional description: Varices oesophageal		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting	Additional description: Vomiting		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Volvulus of small bowel	Additional description: Volvulus of small bowel		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Actinic keratosis	Additional description: Actinic keratosis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot	Additional description: Diabetic foot		

subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema	Additional description: Erythema		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage subcutaneous	Additional description: Haemorrhage subcutaneous		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkeratosis	Additional description: Hyperkeratosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash	Additional description: Rash		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer	Additional description: Skin ulcer		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal and urinary disorders			
Acute kidney injury	Additional description: Acute kidney injury		
subjects affected / exposed	14 / 1306 (1.07%)	13 / 1302 (1.00%)	
occurrences causally related to treatment / all	0 / 14	0 / 14	
deaths causally related to treatment / all	0 / 1	0 / 3	
Bladder disorder	Additional description: Bladder disorder		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary	Additional description: Calculus urinary		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease	Additional description: Chronic kidney disease		
subjects affected / exposed	2 / 1306 (0.15%)	6 / 1302 (0.46%)	
occurrences causally related to treatment / all	0 / 2	1 / 7	
deaths causally related to treatment / all	0 / 1	0 / 1	
Dysuria	Additional description: Dysuria		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria	Additional description: Haematuria		
subjects affected / exposed	9 / 1306 (0.69%)	8 / 1302 (0.61%)	
occurrences causally related to treatment / all	2 / 13	5 / 10	
deaths causally related to treatment / all	0 / 1	0 / 1	
Hydronephrosis	Additional description: Hydronephrosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis	Additional description: Nephrolithiasis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy toxic	Additional description: Nephropathy toxic		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nocturia	Additional description: Nocturia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prerenal failure	Additional description: Prerenal failure		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment	Additional description: Renal impairment		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal pelvis fistula	Additional description: Renal pelvis fistula		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure	Additional description: Renal failure		
subjects affected / exposed	6 / 1306 (0.46%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 3	0 / 0	
Ureteric stenosis	Additional description: Ureteric stenosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis	Additional description: Ureterolithiasis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral haemorrhage	Additional description: Urethral haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention	Additional description: Urinary retention		
subjects affected / exposed	4 / 1306 (0.31%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary bladder haemorrhage	Additional description: Urinary bladder haemorrhage		

subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Hyperparathyroidism	Additional description: Hyperparathyroidism		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia	Additional description: Arthralgia		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis	Additional description: Arthritis		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain	Additional description: Back pain		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Bursitis	Additional description: Bursitis		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis	Additional description: Cervical spinal stenosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis	Additional description: Haemarthrosis		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Haematoma muscle	Additional description: Haematoma muscle		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration	Additional description: Intervertebral disc degeneration		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion	Additional description: Intervertebral disc protrusion		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint effusion	Additional description: Joint effusion		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis	Additional description: Lumbar spinal stenosis		
subjects affected / exposed	6 / 1306 (0.46%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia	Additional description: Myalgia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain	Additional description: Neck pain		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis	Additional description: Osteoarthritis		
subjects affected / exposed	8 / 1306 (0.61%)	10 / 1302 (0.77%)	
occurrences causally related to treatment / all	2 / 8	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity	Additional description: Pain in extremity		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudarthrosis	Additional description: Pseudarthrosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis	Additional description: Rhabdomyolysis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis	Additional description: Rheumatoid arthritis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sacroiliitis	Additional description: Sacroiliitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal infection	Additional description: Abdominal infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis	Additional description: Appendicitis		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis infective	Additional description: Arthritis infective		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia	Additional description: Bacteraemia		

subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary sepsis	Additional description: Biliary sepsis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Brain abscess	Additional description: Brain abscess		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis	Additional description: Bronchitis		
subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis viral	Additional description: Bronchitis viral		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis	Additional description: Cellulitis		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection	Additional description: Clostridium difficile infection		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis	Additional description: Clostridium difficile colitis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Clostridium colitis	Additional description: Clostridium colitis		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Coronavirus infection	Additional description: Coronavirus infection	
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Cystitis	Additional description: Cystitis	
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Device related infection	Additional description: Device related infection	
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)
occurrences causally related to treatment / all	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1
Diverticulitis	Additional description: Diverticulitis	
subjects affected / exposed	6 / 1306 (0.46%)	4 / 1302 (0.31%)
occurrences causally related to treatment / all	1 / 6	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0
Emphysematous pyelonephritis	Additional description: Emphysematous pyelonephritis	
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Empyema	Additional description: Empyema	
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Endocarditis	Additional description: Endocarditis	
subjects affected / exposed	2 / 1306 (0.15%)	3 / 1302 (0.23%)
occurrences causally related to treatment / all	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 2	0 / 0
Enterococcal sepsis	Additional description: Enterococcal sepsis	

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas	Additional description: Erysipelas		
subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Fungal infection	Additional description: Fungal infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer helicobacter	Additional description: Gastric ulcer helicobacter		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis	Additional description: Gastroenteritis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis rotavirus	Additional description: Gastroenteritis rotavirus		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal infection	Additional description: Gastrointestinal infection		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Groin abscess	Additional description: Groin abscess		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cyst infection	Additional description: Hepatic cyst infection		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis E	Additional description: Hepatitis E		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster	Additional description: Herpes zoster		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection	Additional description: Infection		
subjects affected / exposed	4 / 1306 (0.31%)	7 / 1302 (0.54%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza	Additional description: Influenza		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site infection	Additional description: Implant site infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral discitis	Additional description: Intervertebral discitis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lower respiratory tract infection	Additional description: Lower respiratory tract infection		
subjects affected / exposed	4 / 1306 (0.31%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinal abscess	Additional description: Mediastinal abscess		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Myelitis	Additional description: Myelitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis	Additional description: Osteomyelitis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media chronic	Additional description: Otitis media chronic		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic abscess	Additional description: Pancreatic abscess		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papilloma viral infection	Additional description: Papilloma viral infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal	Additional description: Pneumonia pneumococcal		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia	Additional description: Pneumonia		
subjects affected / exposed	58 / 1306 (4.44%)	56 / 1302 (4.30%)	
occurrences causally related to treatment / all	1 / 74	1 / 61	
deaths causally related to treatment / all	1 / 22	0 / 16	
Post procedural infection	Additional description: Post procedural infection		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection	Additional description: Postoperative wound infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pyelonephritis	Additional description: Pyelonephritis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection	Additional description: Respiratory tract infection		
subjects affected / exposed	6 / 1306 (0.46%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinovirus infection	Additional description: Rhinovirus infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis	Additional description: Sepsis		
subjects affected / exposed	3 / 1306 (0.23%)	9 / 1302 (0.69%)	
occurrences causally related to treatment / all	0 / 3	0 / 9	
deaths causally related to treatment / all	0 / 1	0 / 3	
Septic shock	Additional description: Septic shock		
subjects affected / exposed	9 / 1306 (0.69%)	5 / 1302 (0.38%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 7	0 / 3	
Streptococcal endocarditis	Additional description: Streptococcal endocarditis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess	Additional description: Subcutaneous abscess		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superinfection	Additional description: Superinfection		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superinfection bacterial	Additional description: Superinfection bacterial		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection	Additional description: Urinary tract infection		
subjects affected / exposed	23 / 1306 (1.76%)	19 / 1302 (1.46%)	
occurrences causally related to treatment / all	0 / 25	0 / 21	
deaths causally related to treatment / all	0 / 2	0 / 0	
Urosepsis	Additional description: Urosepsis		
subjects affected / exposed	3 / 1306 (0.23%)	7 / 1302 (0.54%)	
occurrences causally related to treatment / all	0 / 3	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 3	
Viral infection	Additional description: Viral infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection	Additional description: Wound infection		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Acidosis	Additional description: Acidosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration	Additional description: Dehydration		

subjects affected / exposed	6 / 1306 (0.46%)	7 / 1302 (0.54%)	
occurrences causally related to treatment / all	0 / 7	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetic ketoacidosis	Additional description: Diabetic ketoacidosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control	Additional description: Diabetes mellitus inadequate control		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus	Additional description: Diabetes mellitus		
subjects affected / exposed	4 / 1306 (0.31%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	1 / 5	0 / 3	
deaths causally related to treatment / all	1 / 1	0 / 0	
Electrolyte imbalance	Additional description: Electrolyte imbalance		
subjects affected / exposed	2 / 1306 (0.15%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout	Additional description: Gout		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia	Additional description: Hyperglycaemia		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia	Additional description: Hyperkalaemia		
subjects affected / exposed	1 / 1306 (0.08%)	4 / 1302 (0.31%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic hyperosmolar nonketotic syndrome	Additional description: Hyperglycaemic hyperosmolar nonketotic syndrome		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperuricaemia	Additional description: Hyperuricaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia	Additional description: Hypokalaemia		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia	Additional description: Hyponatraemia		
subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia	Additional description: Hypoglycaemia		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency	Additional description: Iron deficiency		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis	Additional description: Metabolic acidosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Edoxaban	Placebo	
Total subjects affected by non-serious adverse events subjects affected / exposed	562 / 1306 (43.03%)	534 / 1302 (41.01%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon	Additional description: Adenocarcinoma of colon		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Basal cell carcinoma	Additional description: Basal cell carcinoma		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences (all)	3	3	
Bladder cancer	Additional description: Bladder cancer		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Breast cancer	Additional description: Breast cancer		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences (all)	1	3	
Carcinoma in situ of skin	Additional description: Carcinoma in situ of skin		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Colon cancer	Additional description: Colon cancer		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Colorectal cancer recurrent	Additional description: Colorectal cancer recurrent		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hypergammaglobulinaemia benign monoclonal	Additional description: Hypergammaglobulinaemia benign monoclonal		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Laryngeal cancer	Additional description: Laryngeal cancer		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Malignant melanoma	Additional description: Malignant melanoma		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Malignant melanoma in situ	Additional description: Malignant melanoma in situ		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Lung neoplasm malignant	Additional description: Lung neoplasm malignant		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	2	
Lymphoma	Additional description: Lymphoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Metastases to kidney	Additional description: Metastases to kidney		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Metastases to liver	Additional description: Metastases to liver		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Metastases to lung	Additional description: Metastases to lung		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Myeloproliferative neoplasm	Additional description: Myeloproliferative neoplasm		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Neoplasm	Additional description: Neoplasm		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Plasmacytoma	Additional description: Plasmacytoma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Plasma cell myeloma	Additional description: Plasma cell myeloma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Prostate cancer	Additional description: Prostate cancer		
subjects affected / exposed	7 / 1306 (0.54%)	5 / 1302 (0.38%)	
occurrences (all)	7	5	
Prostate cancer metastatic	Additional description: Prostate cancer metastatic		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Rectal adenocarcinoma	Additional description: Rectal adenocarcinoma		

subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Skin cancer	Additional description: Skin cancer		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	3	
Squamous cell carcinoma	Additional description: Squamous cell carcinoma		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Squamous cell carcinoma of skin	Additional description: Squamous cell carcinoma of skin		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Vascular disorders			
Aortic aneurysm	Additional description: Aortic aneurysm		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences (all)	3	2	
Angiodysplasia	Additional description: Angiodysplasia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Aortic arteriosclerosis	Additional description: Aortic arteriosclerosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Aortic dilatation	Additional description: Aortic dilatation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Aortic stenosis	Additional description: Aortic stenosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Aortic thrombosis	Additional description: Aortic thrombosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Arteriosclerosis	Additional description: Arteriosclerosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Bleeding varicose vein	Additional description: Bleeding varicose vein		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	

Blood pressure fluctuation	Additional description: Blood pressure fluctuation		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Circulatory collapse	Additional description: Circulatory collapse		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Deep vein thrombosis	Additional description: Deep vein thrombosis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Haematoma	Additional description: Haematoma		
subjects affected / exposed	21 / 1306 (1.61%)	17 / 1302 (1.31%)	
occurrences (all)	24	17	
Haemorrhage	Additional description: Haemorrhage		
subjects affected / exposed	4 / 1306 (0.31%)	2 / 1302 (0.15%)	
occurrences (all)	6	2	
Hot flush	Additional description: Hot flush		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Hypertension	Additional description: Hypertension		
subjects affected / exposed	8 / 1306 (0.61%)	10 / 1302 (0.77%)	
occurrences (all)	8	11	
Hypertensive crisis	Additional description: Hypertensive crisis		
subjects affected / exposed	4 / 1306 (0.31%)	4 / 1302 (0.31%)	
occurrences (all)	4	4	
Hypertensive emergency	Additional description: Hypertensive emergency		
subjects affected / exposed	0 / 1306 (0.00%)	3 / 1302 (0.23%)	
occurrences (all)	0	3	
Hypertensive urgency	Additional description: Hypertensive urgency		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hypotension	Additional description: Hypotension		
subjects affected / exposed	13 / 1306 (1.00%)	11 / 1302 (0.84%)	
occurrences (all)	14	12	
Intermittent claudication	Additional description: Intermittent claudication		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	

Orthostatic hypotension	Additional description: Orthostatic hypotension		
subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences (all)	4	1	
Peripheral arterial occlusive disease	Additional description: Peripheral arterial occlusive disease		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Peripheral artery occlusion	Additional description: Peripheral artery occlusion		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Peripheral venous disease	Additional description: Peripheral venous disease		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	3	0	
Phlebitis	Additional description: Phlebitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Raynaud's phenomenon	Additional description: Raynaud's phenomenon		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Superficial vein thrombosis	Additional description: Superficial vein thrombosis		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Subgaleal haematoma	Additional description: Subgaleal haematoma		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Thrombophlebitis	Additional description: Thrombophlebitis		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Thrombosis	Additional description: Thrombosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Varicose ulceration	Additional description: Varicose ulceration		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Varicose vein	Additional description: Varicose vein		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	

Venous thrombosis	Additional description: Venous thrombosis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Surgical and medical procedures			
Arthrodesis	Additional description: Arthrodesis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Bladder neoplasm surgery	Additional description: Bladder neoplasm surgery		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Blepharoplasty	Additional description: Blepharoplasty		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Bunion operation	Additional description: Bunion operation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Cancer surgery	Additional description: Cancer surgery		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences (all)	1	3	
Cardioversion	Additional description: Cardioversion		
subjects affected / exposed	6 / 1306 (0.46%)	9 / 1302 (0.69%)	
occurrences (all)	7	11	
Cardiac resynchronisation therapy	Additional description: Cardiac resynchronisation therapy		
subjects affected / exposed	6 / 1306 (0.46%)	3 / 1302 (0.23%)	
occurrences (all)	6	3	
Cardiac pacemaker replacement	Additional description: Cardiac pacemaker replacement		
subjects affected / exposed	36 / 1306 (2.76%)	39 / 1302 (3.00%)	
occurrences (all)	36	40	
Cardiac pacemaker removal	Additional description: Cardiac pacemaker removal		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Cardiac pacemaker insertion	Additional description: Cardiac pacemaker insertion		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Carpal tunnel decompression	Additional description: Carpal tunnel decompression		

subjects affected / exposed	3 / 1306 (0.23%)	3 / 1302 (0.23%)	
occurrences (all)	3	3	
Cataract operation	Additional description: Cataract operation		
subjects affected / exposed	11 / 1306 (0.84%)	12 / 1302 (0.92%)	
occurrences (all)	15	15	
Catheter management	Additional description: Catheter management		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	3	
Cholelithotomy	Additional description: Cholelithotomy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Coronary arterial stent insertion	Additional description: Coronary arterial stent insertion		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Dental implantation	Additional description: Dental implantation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Endodontic procedure	Additional description: Endodontic procedure		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Electrocauterisation	Additional description: Electrocauterisation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Eye operation	Additional description: Eye operation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Eyelid operation	Additional description: Eyelid operation		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	4	0	
Finger amputation	Additional description: Finger amputation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Gastric polypectomy	Additional description: Gastric polypectomy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Haematoma evacuation	Additional description: Haematoma evacuation		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Hernia repair	Additional description: Hernia repair		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hydrocele operation	Additional description: Hydrocele operation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Internal fixation of fracture	Additional description: Internal fixation of fracture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Inguinal hernia repair	Additional description: Inguinal hernia repair		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Jaw operation	Additional description: Jaw operation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Large intestinal polypectomy	Additional description: Large intestinal polypectomy		
subjects affected / exposed	5 / 1306 (0.38%)	0 / 1302 (0.00%)	
occurrences (all)	5	0	
Knee operation	Additional description: Knee operation		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	3	
Knee arthroplasty	Additional description: Knee arthroplasty		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Liver operation	Additional description: Liver operation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Medical device removal	Additional description: Medical device removal		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Mole excision	Additional description: Mole excision		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Papilloma excision	Additional description: Papilloma excision		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Peripheral artery angioplasty	Additional description: Peripheral artery angioplasty		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Percutaneous coronary intervention	Additional description: Percutaneous coronary intervention		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Prostatic operation	Additional description: Prostatic operation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Radiotherapy to prostate	Additional description: Radiotherapy to prostate		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Rhizolysis	Additional description: Rhizolysis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Sclerotherapy	Additional description: Sclerotherapy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Rhinoplasty	Additional description: Rhinoplasty		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Shoulder operation	Additional description: Shoulder operation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Skin operation	Additional description: Skin operation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Skin lesion removal	Additional description: Skin lesion removal		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Skin neoplasm excision	Additional description: Skin neoplasm excision		
subjects affected / exposed	8 / 1306 (0.61%)	5 / 1302 (0.38%)	
occurrences (all)	10	6	
Toe amputation	Additional description: Toe amputation		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Tooth extraction	Additional description: Tooth extraction		
subjects affected / exposed	11 / 1306 (0.84%)	4 / 1302 (0.31%)	
occurrences (all)	12	4	
Transurethral bladder resection	Additional description: Transurethral bladder resection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Adverse drug reaction	Additional description: Adverse drug reaction		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Asthenia	Additional description: Asthenia		
subjects affected / exposed	18 / 1306 (1.38%)	15 / 1302 (1.15%)	
occurrences (all)	20	17	
Chest discomfort	Additional description: Chest discomfort		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Chest pain	Additional description: Chest pain		
subjects affected / exposed	20 / 1306 (1.53%)	19 / 1302 (1.46%)	
occurrences (all)	21	20	
Complication associated with device	Additional description: Complication associated with device		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Facial pain	Additional description: Facial pain		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Fatigue	Additional description: Fatigue		
subjects affected / exposed	8 / 1306 (0.61%)	11 / 1302 (0.84%)	
occurrences (all)	8	11	
General physical health deterioration	Additional description: General physical health deterioration		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences (all)	3	2	
Gait disturbance	Additional description: Gait disturbance		

subjects affected / exposed	2 / 1306 (0.15%)	4 / 1302 (0.31%)	
occurrences (all)	2	4	
Infusion site extravasation	Additional description: Infusion site extravasation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Inflammation	Additional description: Inflammation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Illness	Additional description: Illness		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Malaise	Additional description: Malaise		
subjects affected / exposed	10 / 1306 (0.77%)	4 / 1302 (0.31%)	
occurrences (all)	10	4	
Non-cardiac chest pain	Additional description: Non-cardiac chest pain		
subjects affected / exposed	7 / 1306 (0.54%)	7 / 1302 (0.54%)	
occurrences (all)	13	7	
Oedema peripheral	Additional description: Oedema peripheral		
subjects affected / exposed	16 / 1306 (1.23%)	19 / 1302 (1.46%)	
occurrences (all)	20	19	
Oedema	Additional description: Oedema		
subjects affected / exposed	6 / 1306 (0.46%)	3 / 1302 (0.23%)	
occurrences (all)	6	3	
Pain	Additional description: Pain		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences (all)	3	0	
Peripheral swelling	Additional description: Peripheral swelling		
subjects affected / exposed	7 / 1306 (0.54%)	7 / 1302 (0.54%)	
occurrences (all)	7	7	
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed	4 / 1306 (0.31%)	5 / 1302 (0.38%)	
occurrences (all)	4	5	
Swelling face	Additional description: Swelling face		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Ulcer	Additional description: Ulcer		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Vaccination site haematoma	Additional description: Vaccination site haematoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Immune system disorders			
Hypersensitivity	Additional description: Hypersensitivity		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Social circumstances			
Breast prosthesis user	Additional description: Breast prosthesis user		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Living in residential institution	Additional description: Living in residential institution		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Reproductive system and breast disorders			
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Breast mass	Additional description: Breast mass		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Erectile dysfunction	Additional description: Erectile dysfunction		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Gynaecomastia	Additional description: Gynaecomastia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Prostatitis	Additional description: Prostatitis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Vaginal haemorrhage	Additional description: Vaginal haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Respiratory, thoracic and mediastinal disorders			

Asthma	Additional description: Asthma		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	2	
Bronchial hyperreactivity	Additional description: Bronchial hyperreactivity		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Bronchitis chronic	Additional description: Bronchitis chronic		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Bronchospasm	Additional description: Bronchospasm		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Chronic obstructive pulmonary disease	Additional description: Chronic obstructive pulmonary disease		
subjects affected / exposed	0 / 1306 (0.00%)	4 / 1302 (0.31%)	
occurrences (all)	0	4	
Cough	Additional description: Cough		
subjects affected / exposed	9 / 1306 (0.69%)	8 / 1302 (0.61%)	
occurrences (all)	10	8	
Diaphragmatic spasm	Additional description: Diaphragmatic spasm		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Dyspnoea exertional	Additional description: Dyspnoea exertional		
subjects affected / exposed	10 / 1306 (0.77%)	6 / 1302 (0.46%)	
occurrences (all)	11	6	
Dyspnoea	Additional description: Dyspnoea		
subjects affected / exposed	43 / 1306 (3.29%)	42 / 1302 (3.23%)	
occurrences (all)	46	50	
Epistaxis	Additional description: Epistaxis		
subjects affected / exposed	48 / 1306 (3.68%)	21 / 1302 (1.61%)	
occurrences (all)	54	22	
Haemoptysis	Additional description: Haemoptysis		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Hiccups	Additional description: Hiccups		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hydrothorax	Additional description: Hydrothorax		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hypoxia	Additional description: Hypoxia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Nasal polyps	Additional description: Nasal polyps		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Nocturnal dyspnoea	Additional description: Nocturnal dyspnoea		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Orthopnoea	Additional description: Orthopnoea		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Pleural effusion	Additional description: Pleural effusion		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	3	1	
Pulmonary fibrosis	Additional description: Pulmonary fibrosis		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Restrictive pulmonary disease	Additional description: Restrictive pulmonary disease		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Respiratory failure	Additional description: Respiratory failure		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Respiratory tract congestion	Additional description: Respiratory tract congestion		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Rhinitis allergic	Additional description: Rhinitis allergic		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Rhinorrhoea	Additional description: Rhinorrhoea		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Sleep apnoea syndrome	Additional description: Sleep apnoea syndrome		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Psychiatric disorders			
Abnormal behaviour	Additional description: Abnormal behaviour		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Anxiety	Additional description: Anxiety		
subjects affected / exposed	4 / 1306 (0.31%)	4 / 1302 (0.31%)	
occurrences (all)	4	4	
Anxiety disorder	Additional description: Anxiety disorder		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Apathy	Additional description: Apathy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Confusional state	Additional description: Confusional state		
subjects affected / exposed	0 / 1306 (0.00%)	3 / 1302 (0.23%)	
occurrences (all)	0	3	
Depressed mood	Additional description: Depressed mood		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Depression	Additional description: Depression		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Disorientation	Additional description: Disorientation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Insomnia	Additional description: Insomnia		
subjects affected / exposed	2 / 1306 (0.15%)	3 / 1302 (0.23%)	
occurrences (all)	2	3	
Mental disorder	Additional description: Mental disorder		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	

Panic attack	Additional description: Panic attack		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Restlessness	Additional description: Restlessness		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Sleep disorder	Additional description: Sleep disorder		
subjects affected / exposed	4 / 1306 (0.31%)	0 / 1302 (0.00%)	
occurrences (all)	4	0	
Product issues			
Device electrical impedance issue	Additional description: Device electrical impedance issue		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Device inappropriate shock delivery	Additional description: Device inappropriate shock delivery		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Device lead damage	Additional description: Device lead damage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Device malfunction	Additional description: Device malfunction		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Device occlusion	Additional description: Device occlusion		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Device stimulation issue	Additional description: Device stimulation issue		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Device lead issue	Additional description: Device lead issue		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Lead dislodgement	Additional description: Lead dislodgement		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Thrombosis in device	Additional description: Thrombosis in device		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
Biliary colic	Additional description: Biliary colic		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Cholelithiasis	Additional description: Cholelithiasis		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Congestive hepatopathy	Additional description: Congestive hepatopathy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Hepatic pain	Additional description: Hepatic pain		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hepatic cyst	Additional description: Hepatic cyst		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Hepatic cirrhosis	Additional description: Hepatic cirrhosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Non-alcoholic steatohepatitis	Additional description: Non-alcoholic steatohepatitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Primary biliary cholangitis	Additional description: Primary biliary cholangitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Investigations			
Angiocardiogram	Additional description: Angiocardiogram		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Angiogram	Additional description: Angiogram		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Arthroscopy	Additional description: Arthroscopy		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Biopsy intestine	Additional description: Biopsy intestine		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Biopsy prostate	Additional description: Biopsy prostate		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Bleeding time prolonged	Additional description: Bleeding time prolonged		
subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences (all)	4	1	
Biopsy lymph gland	Additional description: Biopsy lymph gland		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Blood cholesterol increased	Additional description: Blood cholesterol increased		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Blood creatinine increased	Additional description: Blood creatinine increased		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Body temperature increased	Additional description: Body temperature increased		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Blood magnesium decreased	Additional description: Blood magnesium decreased		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Bronchial aspiration procedure	Additional description: Bronchial aspiration procedure		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Bronchoscopy abnormal	Additional description: Bronchoscopy abnormal		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Catheterisation cardiac	Additional description: Catheterisation cardiac		
subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences (all)	3	1	
Colonoscopy	Additional description: Colonoscopy		

subjects affected / exposed	5 / 1306 (0.38%)	2 / 1302 (0.15%)	
occurrences (all)	5	2	
Coronavirus test positive	Additional description: Coronavirus test positive		
subjects affected / exposed	48 / 1306 (3.68%)	30 / 1302 (2.30%)	
occurrences (all)	49	30	
Cystoscopy	Additional description: Cystoscopy		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Dental examination	Additional description: Dental examination		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Diagnostic procedure	Additional description: Diagnostic procedure		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Echocardiogram	Additional description: Echocardiogram		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Ejection fraction decreased	Additional description: Ejection fraction decreased		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Echocardiogram abnormal	Additional description: Echocardiogram abnormal		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Endoscopy	Additional description: Endoscopy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Endoscopy upper gastrointestinal tract	Additional description: Endoscopy upper gastrointestinal tract		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Glomerular filtration rate decreased	Additional description: Glomerular filtration rate decreased		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Glomerular filtration rate increased	Additional description: Glomerular filtration rate increased		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	

Haemoglobin increased	Additional description: Haemoglobin increased		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Haemoglobin decreased	Additional description: Haemoglobin decreased		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Heart rate increased	Additional description: Heart rate increased		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Heart rate decreased	Additional description: Heart rate decreased		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Hepatic enzyme increased	Additional description: Hepatic enzyme increased		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences (all)	1	3	
International normalised ratio abnormal	Additional description: International normalised ratio abnormal		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Low density lipoprotein increased	Additional description: Low density lipoprotein increased		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Magnetic resonance imaging	Additional description: Magnetic resonance imaging		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Platelet count decreased	Additional description: Platelet count decreased		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Prostatic specific antigen increased	Additional description: Prostatic specific antigen increased		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Radioisotope scan	Additional description: Radioisotope scan		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Rectal ultrasound	Additional description: Rectal ultrasound		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Serum ferritin decreased	Additional description: Serum ferritin decreased		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Sleep study	Additional description: Sleep study		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Spirometry	Additional description: Spirometry		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Troponin increased	Additional description: Troponin increased		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Vitamin D decreased	Additional description: Vitamin D decreased		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Weight decreased	Additional description: Weight decreased		
subjects affected / exposed	5 / 1306 (0.38%)	7 / 1302 (0.54%)	
occurrences (all)	5	8	
Weight increased	Additional description: Weight increased		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Injury, poisoning and procedural complications			
Accidental overdose	Additional description: Accidental overdose		
subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences (all)	5	1	
Animal bite	Additional description: Animal bite		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences (all)	1	3	
Ankle fracture	Additional description: Ankle fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Arthropod bite	Additional description: Arthropod bite		

subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences (all)	3	2	
Bone fissure	Additional description: Bone fissure		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Clavicle fracture	Additional description: Clavicle fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Chest injury	Additional description: Chest injury		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	3	
Contusion	Additional description: Contusion		
subjects affected / exposed	8 / 1306 (0.61%)	4 / 1302 (0.31%)	
occurrences (all)	8	4	
Craniofacial fracture	Additional description: Craniofacial fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Epicondylitis	Additional description: Epicondylitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Eye injury	Additional description: Eye injury		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Eyelid injury	Additional description: Eyelid injury		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Face injury	Additional description: Face injury		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Fall	Additional description: Fall		
subjects affected / exposed	32 / 1306 (2.45%)	31 / 1302 (2.38%)	
occurrences (all)	37	35	
Femur fracture	Additional description: Femur fracture		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Heat exhaustion	Additional description: Heat exhaustion		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Head injury	Additional description: Head injury		
subjects affected / exposed	4 / 1306 (0.31%)	13 / 1302 (1.00%)	
occurrences (all)	5	13	
Hand fracture	Additional description: Hand fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Humerus fracture	Additional description: Humerus fracture		
subjects affected / exposed	1 / 1306 (0.08%)	6 / 1302 (0.46%)	
occurrences (all)	1	6	
Implantation complication	Additional description: Implantation complication		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Injury	Additional description: Injury		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Joint dislocation	Additional description: Joint dislocation		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Joint injury	Additional description: Joint injury		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences (all)	3	2	
Ligament sprain	Additional description: Ligament sprain		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Lower limb fracture	Additional description: Lower limb fracture		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Lumbar vertebral fracture	Additional description: Lumbar vertebral fracture		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Limb injury	Additional description: Limb injury		
subjects affected / exposed	5 / 1306 (0.38%)	7 / 1302 (0.54%)	
occurrences (all)	7	8	
Muscle strain	Additional description: Muscle strain		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Periorbital haematoma	Additional description: Periorbital haematoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Pelvic fracture	Additional description: Pelvic fracture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Periorbital haemorrhage	Additional description: Periorbital haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Post procedural haematoma	Additional description: Post procedural haematoma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Post procedural haemorrhage	Additional description: Post procedural haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Radius fracture	Additional description: Radius fracture		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Rib fracture	Additional description: Rib fracture		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	2	
Scar	Additional description: Scar		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Road traffic accident	Additional description: Road traffic accident		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Shoulder fracture	Additional description: Shoulder fracture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Silicosis	Additional description: Silicosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Skin laceration	Additional description: Skin laceration		

subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)	
occurrences (all)	3	4	
Skin abrasion	Additional description: Skin abrasion		
subjects affected / exposed	2 / 1306 (0.15%)	3 / 1302 (0.23%)	
occurrences (all)	2	3	
Soft tissue injury	Additional description: Soft tissue injury		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Spinal compression fracture	Additional description: Spinal compression fracture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Synovial rupture	Additional description: Synovial rupture		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Wound haemorrhage	Additional description: Wound haemorrhage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Wrist fracture	Additional description: Wrist fracture		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Cardiac disorders			
Angina pectoris	Additional description: Angina pectoris		
subjects affected / exposed	12 / 1306 (0.92%)	8 / 1302 (0.61%)	
occurrences (all)	13	10	
Angina unstable	Additional description: Angina unstable		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Aortic valve stenosis	Additional description: Aortic valve stenosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Arrhythmia	Additional description: Arrhythmia		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Arteriosclerosis coronary artery	Additional description: Arteriosclerosis coronary artery		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	

Atrial fibrillation	Additional description: Atrial fibrillation		
subjects affected / exposed	4 / 1306 (0.31%)	11 / 1302 (0.84%)	
occurrences (all)	6	11	
Atrial tachycardia	Additional description: Atrial tachycardia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Atrial flutter	Additional description: Atrial flutter		
subjects affected / exposed	9 / 1306 (0.69%)	4 / 1302 (0.31%)	
occurrences (all)	10	4	
Bradycardia	Additional description: Bradycardia		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Cardiovascular insufficiency	Additional description: Cardiovascular insufficiency		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Cardiac failure congestive	Additional description: Cardiac failure congestive		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Cardiac failure chronic	Additional description: Cardiac failure chronic		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Cardiac failure	Additional description: Cardiac failure		
subjects affected / exposed	20 / 1306 (1.53%)	18 / 1302 (1.38%)	
occurrences (all)	29	18	
Coronary artery disease	Additional description: Coronary artery disease		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Coronary artery stenosis	Additional description: Coronary artery stenosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Left ventricular dysfunction	Additional description: Left ventricular dysfunction		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Mitral valve stenosis	Additional description: Mitral valve stenosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	

Myocardial fibrosis	Additional description: Myocardial fibrosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Myocardial ischaemia	Additional description: Myocardial ischaemia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Palpitations	Additional description: Palpitations		
subjects affected / exposed	20 / 1306 (1.53%)	7 / 1302 (0.54%)	
occurrences (all)	20	7	
Supraventricular tachycardia	Additional description: Supraventricular tachycardia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Tachyarrhythmia	Additional description: Tachyarrhythmia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Tachycardia	Additional description: Tachycardia		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Ventricular extrasystoles	Additional description: Ventricular extrasystoles		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	3	1	
Ventricular fibrillation	Additional description: Ventricular fibrillation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Ventricular tachycardia	Additional description: Ventricular tachycardia		
subjects affected / exposed	6 / 1306 (0.46%)	3 / 1302 (0.23%)	
occurrences (all)	7	3	
Nervous system disorders			
Ataxia	Additional description: Ataxia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Axonal neuropathy	Additional description: Axonal neuropathy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Balance disorder	Additional description: Balance disorder		

subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Carotid arteriosclerosis	Additional description: Carotid arteriosclerosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Carotid artery stenosis	Additional description: Carotid artery stenosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Carpal tunnel syndrome	Additional description: Carpal tunnel syndrome		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Cerebral ischaemia	Additional description: Cerebral ischaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Cerebral small vessel ischaemic disease	Additional description: Cerebral small vessel ischaemic disease		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Cognitive disorder	Additional description: Cognitive disorder		
subjects affected / exposed	3 / 1306 (0.23%)	5 / 1302 (0.38%)	
occurrences (all)	3	5	
Dementia	Additional description: Dementia		
subjects affected / exposed	3 / 1306 (0.23%)	6 / 1302 (0.46%)	
occurrences (all)	3	6	
Dementia Alzheimer's type	Additional description: Dementia Alzheimer's type		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Depressed level of consciousness	Additional description: Depressed level of consciousness		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Dizziness	Additional description: Dizziness		
subjects affected / exposed	47 / 1306 (3.60%)	46 / 1302 (3.53%)	
occurrences (all)	57	52	
Dysarthria	Additional description: Dysarthria		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	

Dizziness postural	Additional description: Dizziness postural		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Facial paralysis	Additional description: Facial paralysis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Facial paresis	Additional description: Facial paresis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Headache	Additional description: Headache		
subjects affected / exposed	20 / 1306 (1.53%)	19 / 1302 (1.46%)	
occurrences (all)	21	21	
Hemiparesis	Additional description: Hemiparesis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hypoaesthesia	Additional description: Hypoaesthesia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Ischaemic stroke	Additional description: Ischaemic stroke		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Intracranial aneurysm	Additional description: Intracranial aneurysm		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Lethargy	Additional description: Lethargy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Loss of consciousness	Additional description: Loss of consciousness		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Memory impairment	Additional description: Memory impairment		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Neuralgia	Additional description: Neuralgia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	

Ophthalmic migraine	Additional description: Ophthalmic migraine		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Parkinson's disease	Additional description: Parkinson's disease		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences (all)	1	3	
Paraesthesia	Additional description: Paraesthesia		
subjects affected / exposed	6 / 1306 (0.46%)	2 / 1302 (0.15%)	
occurrences (all)	6	2	
Polyneuropathy	Additional description: Polyneuropathy		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Presyncope	Additional description: Presyncope		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Sciatica	Additional description: Sciatica		
subjects affected / exposed	3 / 1306 (0.23%)	5 / 1302 (0.38%)	
occurrences (all)	3	5	
Seizure	Additional description: Seizure		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Somnolence	Additional description: Somnolence		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Speech disorder	Additional description: Speech disorder		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Syncope	Additional description: Syncope		
subjects affected / exposed	15 / 1306 (1.15%)	11 / 1302 (0.84%)	
occurrences (all)	16	14	
Tremor	Additional description: Tremor		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Vascular dementia	Additional description: Vascular dementia		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	3	

Blood and lymphatic system disorders			
Anaemia	Additional description: Anaemia		
subjects affected / exposed	12 / 1306 (0.92%)	8 / 1302 (0.61%)	
occurrences (all)	13	8	
Blood disorder	Additional description: Blood disorder		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Iron deficiency anaemia	Additional description: Iron deficiency anaemia		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences (all)	4	2	
Lymph node calcification	Additional description: Lymph node calcification		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Lymphadenopathy	Additional description: Lymphadenopathy		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Microcytic anaemia	Additional description: Microcytic anaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Nephrogenic anaemia	Additional description: Nephrogenic anaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Normochromic anaemia	Additional description: Normochromic anaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Normocytic anaemia	Additional description: Normocytic anaemia		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences (all)	1	3	
Ear and labyrinth disorders			
Auricular swelling	Additional description: Auricular swelling		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Ear pain	Additional description: Ear pain		

subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Meniere's disease	Additional description: Meniere's disease		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Tinnitus	Additional description: Tinnitus		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Tympanic membrane perforation	Additional description: Tympanic membrane perforation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Vertigo	Additional description: Vertigo		
subjects affected / exposed	8 / 1306 (0.61%)	7 / 1302 (0.54%)	
occurrences (all)	9	8	
Eye disorders			
Amaurosis fugax	Additional description: Amaurosis fugax		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Age-related macular degeneration	Additional description: Age-related macular degeneration		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Blepharitis	Additional description: Blepharitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Cataract	Additional description: Cataract		
subjects affected / exposed	9 / 1306 (0.69%)	7 / 1302 (0.54%)	
occurrences (all)	11	8	
Cataract nuclear	Additional description: Cataract nuclear		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Charles Bonnet syndrome	Additional description: Charles Bonnet syndrome		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Choroidal haemorrhage	Additional description: Choroidal haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	

Conjunctival hyperaemia	Additional description: Conjunctival hyperaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Conjunctival irritation	Additional description: Conjunctival irritation		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Conjunctival haemorrhage	Additional description: Conjunctival haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Dacryostenosis acquired	Additional description: Dacryostenosis acquired		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Dermatochalasis	Additional description: Dermatochalasis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Eye haemorrhage	Additional description: Eye haemorrhage		
subjects affected / exposed	3 / 1306 (0.23%)	3 / 1302 (0.23%)	
occurrences (all)	3	3	
Eye pain	Additional description: Eye pain		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences (all)	3	0	
Eye inflammation	Additional description: Eye inflammation		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Eyelid bleeding	Additional description: Eyelid bleeding		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Lacrimation increased	Additional description: Lacrimation increased		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	3	
Macular degeneration	Additional description: Macular degeneration		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Maculopathy	Additional description: Maculopathy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	

Ocular hyperaemia	Additional description: Ocular hyperaemia		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Optic disc haemorrhage	Additional description: Optic disc haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Retinal detachment	Additional description: Retinal detachment		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Retinal haemorrhage	Additional description: Retinal haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Retinal tear	Additional description: Retinal tear		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Retinal vein occlusion	Additional description: Retinal vein occlusion		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Uveitis	Additional description: Uveitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Vision blurred	Additional description: Vision blurred		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Visual acuity reduced	Additional description: Visual acuity reduced		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Visual impairment	Additional description: Visual impairment		
subjects affected / exposed	3 / 1306 (0.23%)	5 / 1302 (0.38%)	
occurrences (all)	8	5	
Vitreous floaters	Additional description: Vitreous floaters		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Vitreous haemorrhage	Additional description: Vitreous haemorrhage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	

Gastrointestinal disorders			
Abdominal distension	Additional description: Abdominal distension		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Abdominal discomfort	Additional description: Abdominal discomfort		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Abdominal hernia	Additional description: Abdominal hernia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Abdominal pain	Additional description: Abdominal pain		
subjects affected / exposed	9 / 1306 (0.69%)	16 / 1302 (1.23%)	
occurrences (all)	9	19	
Abdominal pain upper	Additional description: Abdominal pain upper		
subjects affected / exposed	10 / 1306 (0.77%)	3 / 1302 (0.23%)	
occurrences (all)	10	3	
Anal fissure	Additional description: Anal fissure		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Anal haemorrhage	Additional description: Anal haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Aphthous ulcer	Additional description: Aphthous ulcer		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Colitis	Additional description: Colitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Constipation	Additional description: Constipation		
subjects affected / exposed	4 / 1306 (0.31%)	8 / 1302 (0.61%)	
occurrences (all)	5	8	
Diaphragmatic hernia	Additional description: Diaphragmatic hernia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Diarrhoea	Additional description: Diarrhoea		

subjects affected / exposed	19 / 1306 (1.45%)	20 / 1302 (1.54%)	
occurrences (all)	20	21	
Diverticulum	Additional description: Diverticulum		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Diverticulum intestinal	Additional description: Diverticulum intestinal		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Dry mouth	Additional description: Dry mouth		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Duodenitis	Additional description: Duodenitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Dyspepsia	Additional description: Dyspepsia		
subjects affected / exposed	3 / 1306 (0.23%)	5 / 1302 (0.38%)	
occurrences (all)	3	5	
Dysphagia	Additional description: Dysphagia		
subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences (all)	4	3	
Flatulence	Additional description: Flatulence		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Frequent bowel movements	Additional description: Frequent bowel movements		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Gastrooesophageal reflux disease	Additional description: Gastrooesophageal reflux disease		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Gastrointestinal pain	Additional description: Gastrointestinal pain		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Gastrointestinal haemorrhage	Additional description: Gastrointestinal haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Gastrointestinal disorder	Additional description: Gastrointestinal disorder		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Gastritis erosive	Additional description: Gastritis erosive		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Gastritis	Additional description: Gastritis		
subjects affected / exposed	7 / 1306 (0.54%)	8 / 1302 (0.61%)	
occurrences (all)	7	8	
Gingival bleeding	Additional description: Gingival bleeding		
subjects affected / exposed	7 / 1306 (0.54%)	2 / 1302 (0.15%)	
occurrences (all)	7	2	
Haematochezia	Additional description: Haematochezia		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Haemorrhoids	Additional description: Haemorrhoids		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences (all)	5	2	
Haemorrhoidal haemorrhage	Additional description: Haemorrhoidal haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	3	0	
Inguinal hernia	Additional description: Inguinal hernia		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Intestinal obstruction	Additional description: Intestinal obstruction		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Intestinal haemorrhage	Additional description: Intestinal haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Large intestine polyp	Additional description: Large intestine polyp		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Lower gastrointestinal haemorrhage	Additional description: Lower gastrointestinal haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Lip haemorrhage	Additional description: Lip haemorrhage		

subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Melaena	Additional description: Melaena		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Mouth haemorrhage	Additional description: Mouth haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Nausea	Additional description: Nausea		
subjects affected / exposed	21 / 1306 (1.61%)	11 / 1302 (0.84%)	
occurrences (all)	21	11	
Oesophageal stenosis	Additional description: Oesophageal stenosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Oesophagitis	Additional description: Oesophagitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Pancreatitis	Additional description: Pancreatitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	2	
Peritoneal cyst	Additional description: Peritoneal cyst		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Rectal haemorrhage	Additional description: Rectal haemorrhage		
subjects affected / exposed	9 / 1306 (0.69%)	5 / 1302 (0.38%)	
occurrences (all)	9	6	
Rectal prolapse	Additional description: Rectal prolapse		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Rectal tenesmus	Additional description: Rectal tenesmus		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Reflux gastritis	Additional description: Reflux gastritis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Toothache	Additional description: Toothache		

subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Trichoglossia	Additional description: Trichoglossia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Varices oesophageal	Additional description: Varices oesophageal		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Vomiting	Additional description: Vomiting		
subjects affected / exposed	3 / 1306 (0.23%)	5 / 1302 (0.38%)	
occurrences (all)	3	5	
Skin and subcutaneous tissue disorders			
Actinic keratosis	Additional description: Actinic keratosis		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences (all)	3	0	
Alopecia	Additional description: Alopecia		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	3	
Blister	Additional description: Blister		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Chronic papillomatous dermatitis	Additional description: Chronic papillomatous dermatitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Decubitus ulcer	Additional description: Decubitus ulcer		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences (all)	3	0	
Dermatitis	Additional description: Dermatitis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Dermal cyst	Additional description: Dermal cyst		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Dermatitis contact	Additional description: Dermatitis contact		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	

Dermatosis	Additional description: Dermatosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Eczema	Additional description: Eczema		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Erythema	Additional description: Erythema		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences (all)	1	3	
Hirsutism	Additional description: Hirsutism		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hyperhidrosis	Additional description: Hyperhidrosis		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Hyperkeratosis	Additional description: Hyperkeratosis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Ingrowing nail	Additional description: Ingrowing nail		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Lichen planus	Additional description: Lichen planus		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Petechiae	Additional description: Petechiae		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Pruritus	Additional description: Pruritus		
subjects affected / exposed	13 / 1306 (1.00%)	8 / 1302 (0.61%)	
occurrences (all)	13	8	
Psoriasis	Additional description: Psoriasis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Purpura	Additional description: Purpura		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	

Rash	Additional description: Rash		
subjects affected / exposed	10 / 1306 (0.77%)	9 / 1302 (0.69%)	
occurrences (all)	11	12	
Rash pruritic	Additional description: Rash pruritic		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	4	1	
Skin haemorrhage	Additional description: Skin haemorrhage		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Skin lesion	Additional description: Skin lesion		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Skin ulcer	Additional description: Skin ulcer		
subjects affected / exposed	4 / 1306 (0.31%)	2 / 1302 (0.15%)	
occurrences (all)	4	2	
Stasis dermatitis	Additional description: Stasis dermatitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Telangiectasia	Additional description: Telangiectasia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Urticaria	Additional description: Urticaria		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Xeroderma	Additional description: Xeroderma		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Acute kidney injury	Additional description: Acute kidney injury		
subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences (all)	3	1	
Bladder wall calcification	Additional description: Bladder wall calcification		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Chronic kidney disease	Additional description: Chronic kidney disease		

subjects affected / exposed	5 / 1306 (0.38%)	0 / 1302 (0.00%)	
occurrences (all)	6	0	
Dysuria	Additional description: Dysuria		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	4	1	
Haematuria	Additional description: Haematuria		
subjects affected / exposed	31 / 1306 (2.37%)	8 / 1302 (0.61%)	
occurrences (all)	41	10	
Nocturia	Additional description: Nocturia		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Oliguria	Additional description: Oliguria		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Polyuria	Additional description: Polyuria		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Proteinuria	Additional description: Proteinuria		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Renal colic	Additional description: Renal colic		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Renal impairment	Additional description: Renal impairment		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Renal pain	Additional description: Renal pain		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Renal failure	Additional description: Renal failure		
subjects affected / exposed	3 / 1306 (0.23%)	2 / 1302 (0.15%)	
occurrences (all)	3	2	
Urinary retention	Additional description: Urinary retention		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Urinary incontinence	Additional description: Urinary incontinence		

subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Urinary bladder haemorrhage	Additional description: Urinary bladder haemorrhage		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Endocrine disorders			
Graves' disease	Additional description: Graves' disease		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Hyperthyroidism	Additional description: Hyperthyroidism		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Hypothyroidism	Additional description: Hypothyroidism		
subjects affected / exposed	4 / 1306 (0.31%)	3 / 1302 (0.23%)	
occurrences (all)	4	3	
Musculoskeletal and connective tissue disorders			
Arthralgia	Additional description: Arthralgia		
subjects affected / exposed	18 / 1306 (1.38%)	24 / 1302 (1.84%)	
occurrences (all)	23	27	
Arthritis	Additional description: Arthritis		
subjects affected / exposed	0 / 1306 (0.00%)	3 / 1302 (0.23%)	
occurrences (all)	0	3	
Back pain	Additional description: Back pain		
subjects affected / exposed	11 / 1306 (0.84%)	19 / 1302 (1.46%)	
occurrences (all)	11	25	
Bone pain	Additional description: Bone pain		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Bursitis	Additional description: Bursitis		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Chondrocalcinosis	Additional description: Chondrocalcinosis		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Groin pain	Additional description: Groin pain		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Haematoma muscle	Additional description: Haematoma muscle		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Intervertebral disc protrusion	Additional description: Intervertebral disc protrusion		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Joint microhaemorrhage	Additional description: Joint microhaemorrhage		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Joint swelling	Additional description: Joint swelling		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Lumbar spinal stenosis	Additional description: Lumbar spinal stenosis		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	3	1	
Muscular weakness	Additional description: Muscular weakness		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Muscle fatigue	Additional description: Muscle fatigue		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Muscle spasms	Additional description: Muscle spasms		
subjects affected / exposed	6 / 1306 (0.46%)	0 / 1302 (0.00%)	
occurrences (all)	6	0	
Muscle twitching	Additional description: Muscle twitching		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Mobility decreased	Additional description: Mobility decreased		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Musculoskeletal chest pain	Additional description: Musculoskeletal chest pain		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Myalgia	Additional description: Myalgia		

subjects affected / exposed	4 / 1306 (0.31%)	1 / 1302 (0.08%)	
occurrences (all)	4	1	
Myopathy	Additional description: Myopathy		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Neck pain	Additional description: Neck pain		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Musculoskeletal stiffness	Additional description: Musculoskeletal stiffness		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Osteoarthritis	Additional description: Osteoarthritis		
subjects affected / exposed	9 / 1306 (0.69%)	3 / 1302 (0.23%)	
occurrences (all)	10	4	
Osteochondrosis	Additional description: Osteochondrosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Osteonecrosis	Additional description: Osteonecrosis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Osteopenia	Additional description: Osteopenia		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Osteoporosis	Additional description: Osteoporosis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Pain in extremity	Additional description: Pain in extremity		
subjects affected / exposed	9 / 1306 (0.69%)	15 / 1302 (1.15%)	
occurrences (all)	9	16	
Periarthritis	Additional description: Periarthritis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Polymyalgia rheumatica	Additional description: Polymyalgia rheumatica		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Rheumatic disorder	Additional description: Rheumatic disorder		

subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Spinal osteoarthritis	Additional description: Spinal osteoarthritis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Spondylolisthesis	Additional description: Spondylolisthesis		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Tendonitis	Additional description: Tendonitis		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Vertebral lesion	Additional description: Vertebral lesion		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Bacteriuria	Additional description: Bacteriuria		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Bronchitis	Additional description: Bronchitis		
subjects affected / exposed	5 / 1306 (0.38%)	7 / 1302 (0.54%)	
occurrences (all)	5	7	
Candida infection	Additional description: Candida infection		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Cellulitis	Additional description: Cellulitis		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	3	2	
Chronic sinusitis	Additional description: Chronic sinusitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Conjunctivitis	Additional description: Conjunctivitis		
subjects affected / exposed	6 / 1306 (0.46%)	2 / 1302 (0.15%)	
occurrences (all)	6	2	
Cystitis	Additional description: Cystitis		
subjects affected / exposed	5 / 1306 (0.38%)	2 / 1302 (0.15%)	
occurrences (all)	6	2	

Dacryocystitis	Additional description: Dacryocystitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Diverticulitis	Additional description: Diverticulitis		
subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	2	1	
Ear infection	Additional description: Ear infection		
subjects affected / exposed	3 / 1306 (0.23%)	0 / 1302 (0.00%)	
occurrences (all)	4	0	
Ear infection fungal	Additional description: Ear infection fungal		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Endocarditis	Additional description: Endocarditis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Erysipelas	Additional description: Erysipelas		
subjects affected / exposed	2 / 1306 (0.15%)	2 / 1302 (0.15%)	
occurrences (all)	2	2	
Eye infection	Additional description: Eye infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	2	
Folliculitis	Additional description: Folliculitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal infection	Additional description: Gastrointestinal infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Gastroenteritis viral	Additional description: Gastroenteritis viral		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Fungal skin infection	Additional description: Fungal skin infection		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Fungal infection	Additional description: Fungal infection		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	

Gastroenteritis	Additional description: Gastroenteritis		
subjects affected / exposed	1 / 1306 (0.08%)	3 / 1302 (0.23%)	
occurrences (all)	1	3	
Herpes zoster	Additional description: Herpes zoster		
subjects affected / exposed	2 / 1306 (0.15%)	3 / 1302 (0.23%)	
occurrences (all)	2	3	
Infected dermal cyst	Additional description: Infected dermal cyst		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Implant site infection	Additional description: Implant site infection		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Impetigo	Additional description: Impetigo		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Influenza	Additional description: Influenza		
subjects affected / exposed	1 / 1306 (0.08%)	1 / 1302 (0.08%)	
occurrences (all)	1	1	
Lower respiratory tract infection	Additional description: Lower respiratory tract infection		
subjects affected / exposed	3 / 1306 (0.23%)	6 / 1302 (0.46%)	
occurrences (all)	3	8	
Liver abscess	Additional description: Liver abscess		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Localised infection	Additional description: Localised infection		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Lyme disease	Additional description: Lyme disease		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Nasopharyngitis	Additional description: Nasopharyngitis		
subjects affected / exposed	6 / 1306 (0.46%)	11 / 1302 (0.84%)	
occurrences (all)	6	11	
Orchitis	Additional description: Orchitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	

Pharyngitis	Additional description: Pharyngitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Pneumonia	Additional description: Pneumonia		
subjects affected / exposed	5 / 1306 (0.38%)	4 / 1302 (0.31%)	
occurrences (all)	5	4	
Pulpitis dental	Additional description: Pulpitis dental		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	4	0	
Pyelonephritis	Additional description: Pyelonephritis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Respiratory tract infection	Additional description: Respiratory tract infection		
subjects affected / exposed	6 / 1306 (0.46%)	8 / 1302 (0.61%)	
occurrences (all)	6	11	
Rhinitis	Additional description: Rhinitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Sinusitis	Additional description: Sinusitis		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Tinea pedis	Additional description: Tinea pedis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Tooth infection	Additional description: Tooth infection		
subjects affected / exposed	2 / 1306 (0.15%)	3 / 1302 (0.23%)	
occurrences (all)	2	3	
Upper respiratory tract infection	Additional description: Upper respiratory tract infection		
subjects affected / exposed	1 / 1306 (0.08%)	5 / 1302 (0.38%)	
occurrences (all)	1	5	
Tooth abscess	Additional description: Tooth abscess		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Urinary tract infection	Additional description: Urinary tract infection		
subjects affected / exposed	18 / 1306 (1.38%)	19 / 1302 (1.46%)	
occurrences (all)	33	24	

Urosepsis	Additional description: Urosepsis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Viral infection	Additional description: Viral infection		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Wound infection	Additional description: Wound infection		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	3	
Vestibular neuronitis	Additional description: Vestibular neuronitis		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Cachexia	Additional description: Cachexia		
subjects affected / exposed	1 / 1306 (0.08%)	2 / 1302 (0.15%)	
occurrences (all)	1	2	
Decreased appetite	Additional description: Decreased appetite		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Dehydration	Additional description: Dehydration		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	
Diabetes mellitus	Additional description: Diabetes mellitus		
subjects affected / exposed	7 / 1306 (0.54%)	4 / 1302 (0.31%)	
occurrences (all)	7	4	
Folate deficiency	Additional description: Folate deficiency		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Gout	Additional description: Gout		
subjects affected / exposed	3 / 1306 (0.23%)	4 / 1302 (0.31%)	
occurrences (all)	3	4	
Hypercholesterolaemia	Additional description: Hypercholesterolaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hyperglycaemia	Additional description: Hyperglycaemia		

subjects affected / exposed	2 / 1306 (0.15%)	1 / 1302 (0.08%)	
occurrences (all)	4	1	
Hyperkalaemia	Additional description: Hyperkalaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hyperlipidaemia	Additional description: Hyperlipidaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hypertriglyceridaemia	Additional description: Hypertriglyceridaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Hyperuricaemia	Additional description: Hyperuricaemia		
subjects affected / exposed	3 / 1306 (0.23%)	3 / 1302 (0.23%)	
occurrences (all)	3	3	
Hypoglycaemia	Additional description: Hypoglycaemia		
subjects affected / exposed	2 / 1306 (0.15%)	0 / 1302 (0.00%)	
occurrences (all)	2	0	
Impaired fasting glucose	Additional description: Impaired fasting glucose		
subjects affected / exposed	0 / 1306 (0.00%)	1 / 1302 (0.08%)	
occurrences (all)	0	1	
Hypokalaemia	Additional description: Hypokalaemia		
subjects affected / exposed	1 / 1306 (0.08%)	0 / 1302 (0.00%)	
occurrences (all)	1	0	
Iron deficiency	Additional description: Iron deficiency		
subjects affected / exposed	3 / 1306 (0.23%)	1 / 1302 (0.08%)	
occurrences (all)	4	1	
Type 2 diabetes mellitus	Additional description: Type 2 diabetes mellitus		
subjects affected / exposed	0 / 1306 (0.00%)	2 / 1302 (0.15%)	
occurrences (all)	0	2	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 December 2017	• CHA2DS2VASc as used within NOAH and defined in section inclusion criteria does not contain female sex (modified CHA2DS2VASc score) • Correction of typographical error: pglycoprotein inhibitors instead of glycoprotein p inhibitors • The Steering Committee decided to add the secondary outcome parameter Major Adverse Cardiac Events [MACEs] (cardiac death, myocardial infarction, acute coronary syndrome) to allow direct comparison with outcome of other published studies (e.g. RELY and ENGAGE). • Harmonisation of protocol versions by adding the legal exclusion criterion (applicable in countries where legally required): "E.12. All persons exempt from participation in a clinical trial by law." which was requested by the French ethics committee and included in the protocol version 10.10.2016 that was valid in France, only. • Adaption of storage conditions for study medication from 1-25°C to 2-25°C. • SmPC is used as reference throughout the entire study protocol. • Definition of temporary discontinuation of study medication in case of clinical indication for temporary antiplatelet agent prescription in addition to study medication (≤ 6 months duration) • Adaption of allowed time window for scheduled follow-up visits from +/- 1 month to +/-2 weeks with regard to logistics of study medication as IMP is being provided in units, each sufficient for 6 months plus 14 days reserve. • Actual weight is part of every physical examination and also needed to determine the adequate dosage of the IMP. Measuring body weight was explicitly added to the measures of the baseline and drug/device visits. • Addition of a fourth member of the Endpoint Review Committee (ERC) to facilitate timely adjudication of SAEs and to ensure greater flexibility in case of temporary unavailability of an ERC member.

27 April 2018	• The modified CHA2DS2VASc score definitions were adapted to guideline definitions in one point in order to make results comparable to other clinical trials. "Previous myocardial infection" was added to the subgroup of vascular diseases. • Reduction of total number of patients needed from 3,400 to 2,686 as a consequence of prolonged mean follow-up period. In addition it was clarified that the expected number of patients is described as patients who have been randomised and took at least one does of study drug (randomised and treated). • Prolongation of recruitment duration after recalculation by the study statistician also prolonged follow-up time of already included patients. • Generalisation of I2. and I3. as patients are selected during clinical routine visits and the device settings are according to clinical routine care. By protocol definitions any AHRE detected by the device in the past is valid if the atrial rate is ≥ 180 bpm and the duration ≥ 6 min.
06 November 2018	The use of defibrillator and insertable cardiac monitor were amended to main inclusion criteria for study population. • Definition of AHRE was reduced to > 170 bmp atrial rate. • Secondary outcome parameter: Major Adverse Cardiac Events was specified to cardiovascular death, myocardial infarction, acute coronary syndrome, PCI, CABG. • Secondary outcome parameter: storke or systemic arterial embolism was added. • Safety analysis will be perfomed with all patients enrolled.
01 December 2019	• Number of patients was reduced to randomised and treated 2,538 patients. • Number or primary endpoints was reduced to n= 220. • Recruitment period was expanded to n= 71 months. • Maximum follow up time was increased to n= 83 months. • Total study duration was increased to n= 90 months.
01 October 2020	• Measures to be taken in case of pandemic was added.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The trial does not have sufficient power to detect or rule out a small beneficial effect of oral anticoagulation on the prevention of stroke. The generalizability of these findings with edoxaban to other NOACs is not known.

Notes:

Online references

http://www.ncbi.nlm.nih.gov/pubmed/37622677